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Maintenance of Beta Cell Identity and Function 
Giselle Dominguez Gutierrez 
 
The acquisition of beta cell identity and function is a multistage process that involves the 
sequential regulation of specific factors and signals. The maintenance of beta cell identity and 
function is a process of comparable importance that requires persistent and continuous 
regulation. Loss of beta cell identity and/or reprogramming represents an important feature of 
beta cell dysfunction in genetic models of diabetes, as well as in patients with type 1 and type 2 
diabetes. The factors and mechanisms involved in the acquisition and maintenance of beta cell 
identity are still not well understood. Nevertheless, several beta cell developmental transcription 
factors have been found to be important in the maintenance of its functional identity during the 
postnatal stage.  
Nkx2.2 is a transcription factor that is critical for the development and differentiation of beta 
cells both in mice and humans. In adults, Nkx2.2 is expressed in the entire beta cell population. 
However, due to the perinatal lethality of the Nkx2.2 null mice, the study of its function in adult 
beta cells has remained elusive. For my dissertation work, I explored the function and 
mechanism of action of Nkx2.2 in the adult beta cell. I deleted Nkx2.2 specifically in beta cells 
during their maturation and in adults. Deletion of Nkx2.2 in beta cells caused rapid onset of 
diabetes due to the loss of insulin and the down-regulation of many beta cell functional genes. 
Concomitantly, Nkx2.2-deficient beta cells acquired non-beta cell endocrine features, resulting in 
populations of completely reprogrammed cells and bi-hormonal cells that have hybrid endocrine 
cell morphological characteristics.  
	
Molecular analysis in mouse and human islets revealed that Nkx2.2 is a conserved master 
regulatory protein that controls the acquisition and maintenance of a functional monohormonal 
beta cell identity by directly activating critical beta cell genes, and actively repressing genes that 
specify the alternative islet endocrine cell lineages. This study demonstrates the highly volatile 
nature of the beta cell; it is necessary to actively maintain expression of genes involved in beta 
cell function, but to also maintain repression of closely related endocrine gene programs. These 
findings have potential applications that include the optimization of iPS cell differentiation 
protocols that aim to differentiate functional beta cells that remain safely locked into that identity 
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Diabetes is a condition where the body is unable to produce or utilize enough insulin to cope 
with elevated blood glucose levels. This chronic condition has become a very important 
healthcare concern, positioning itself as a major cause of death in most countries around the 
globe. According to the International Diabetes Federation, there are currently an estimated 415 
million adults living with diabetes. In addition, there are also 318 million additional individuals 
who present with glucose intolerance and are therefore at risk of developing this disease. The 
number of diabetic individuals is expected to increase to 642 million people by 2040 
(Federation., 2015). Furthermore, the financial cost associated with the prevention or 
management of diabetes and its complications was estimated to range between $672 billion to 
$1,197 billion, which represents 12% of the global healthcare expenditure. More importantly, 
this condition imposes a significant burden on the patient lives and their families, by having to 
cope with the different complications that are associated with diabetes, including cardiovascular 
disease, kidney, nerve and eye disease. 
 
There are two major forms of diabetes, type I and type II diabetes (American Diabetes, 2014).  
Type I diabetes (T1D), is a chronic condition characterized by immune dysregulation, where the 
pancreatic insulin-producing beta cells are attacked and destroyed by the immune system. As a 
result of the autoimmunity, patients are unable to produce sufficient amounts of insulin and are 
therefore dependent on taking multiple doses of this hormone daily.  
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The onset of T1D primarily occurs in children and young adults. In addition, the incidence of 
T1D is increasing around the globe, and although there is a strong underlying genetic 
component, the trigger for the development of T1D remains unknown (Federation., 2015).  There 
is still much debate in the etiology of this disease; both environmental and genetic factors are 
believed to contribute to its development and progression. Additionally, recent studies have 
suggested that insulin-producing beta cells could play a critical role in their own demise 
(Atkinson, 2012; Soleimanpour and Stoffers, 2013).  
 
Type 2 diabetes (T2D) is the most prevalent form of diabetes, and is mainly characterized by 
insulin resistance in the peripheral organs and/or defects in pancreatic beta cell function. The 
origin of T2D is associated with a combination of genetic and environmental factors. Some of 
the environmental factors include a lack of proper nutrition and physical activity (Olokoba et al., 
2012). Although T2D occurs more commonly in adults, it is now increasingly seen in children 
and adolescents (IDF –atlas ref). Metabolic dysfunction of peripheral tissues, such as liver and 
fat can contribute to the development of T2D. However, a decrease in beta cell function has been 
identified as a very important hallmark in both the development and progression of disease 
(Prentki and Nolan, 2006; Tahrani et al., 2011; Ward et al., 1984). Accordingly, recent studies 
have identified genes important for beta cell development, function and identity to be associated 
with T2D risk variants. These genes are not only expressed in beta cells, but are also 




One of the main features observed in both T1D and T2D is a gradual loss of beta cell mass, 
which had previously been thought to occur primarily through beta cell death. (Butler et al., 
2003; Clark et al., 1988; Eisenbarth, 1986; Eizirik and Mandrup-Poulsen, 2001; Sakuraba et al., 
2002). Recent studies, however, have led to alternative explanations for the apparent loss of beta 
cells. Talchai and colleagues (Talchai et al., 2012) used genetically modified mice to ablate 
FoxO1 in beta cells, and found that loss of beta cell identity and not apoptosis was in fact the 
trigger for the development of diabetes in these mice. Interestingly, beta cells lacking FoxO1 
were found to first dedifferentiate, followed by the expression of other islet hormones, such as 
glucagon, somatostatin and pancreatic polypeptide. Furthermore, Talchai et al. showed that beta 
cell dedifferentiation was not a unique feature of FoxO1 mutant mice, but was also present in 
several other diabetic mouse models.  These findings provide strong evidence that maintenance 
of beta cell identity is crucial for the proper function of the beta cell during physiological and 
pathophysiological conditions. Moreover, it sheds light on the high level of plasticity that the 
beta cell possesses, a feature that provides immense therapeutic potential. 
 
Current Treatments 
The discovery of insulin in 1921-1922 represented a major advancement in the treatment of 
diabetes, especially for T1D (Rosenfeld, 2002). Currently, insulin is given in daily doses to 
patients either through injections or via insulin pumps, which have become more widely used in 
the past decade. Although, great advances have been made in the optimization of insulin therapy, 
precise metabolic control that can avoid all of the complications that arise from diabetes has not 
yet been achieved (Atkinson et al., 2014).  For many years, significant effort has also been put 
into the development of immunotherapies to prevent or attenuate the autoimmune response.  
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These therapies range from antigen specific approaches and cell therapy to cytokine and anti-
inflammatory treatments. Although several therapies have been tested in clinical trials, any 
success in disease attenuation have been transient and have not yet resulted in complete 
remission and insulin independence. Additionally, toxicity side effects remain a central concern 
(Ben Nasr et al., 2015).  
 
An alternative treatment for patients with diabetes is islet transplantation, for which the first 
successful experiments in rats date back to the 1970s (Ballinger and Lacy, 1972) and subsequent 
trials in humans occurred in 1980 (Najarian et al., 1980). The success of this procedure 
culminated in 2000 when seven T1D patients attained normoglycemia after this procedure, 
widely known as the Edmonton protocol (Shapiro et al., 2000). Since this breakthrough, 
scientists have made significant advances in the optimization of this protocol. Patients who 
receive such transplants are able to reduce or eliminate insulin injections for a period of time that 
can vary from months to years, thereby preventing disease-related complications (Froud et al., 
2005; O'Connell et al., 2006; Toso et al., 2006). Nonetheless, there is a very short supply of 
human islets, limiting the availability of treatments for all the patients, particularly since each 
patient generally requires islets from more than one donor. Additionally, one of the biggest 
challenges associated with this procedure is the rejection of the transplanted beta cells by the 
immune system, which can reduce patient lifespan significantly. In an effort to overcome this 
issue, patients have to continually take immunosuppressant drugs post-transplantation, which can 
have deleterious systemic side effects. Furthermore, the long-term side effects of this 
immunosuppressive regimen remain unknown (Hafiz et al., 2005; Hirshberg et al., 2003). 
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The management and development of therapies for diabetes poses a great challenge to both 
doctors and scientists alike. The current treatment for T2D involves lifestyle interventions in 
combination with different kinds of pharmacological agents.  Lifestyle interventions mainly 
include a proper diet and regular exercise, which can be helpful in managing diabetes (Jeon et 
al., 2007; Sigal et al., 2006); however, it is difficult for many patients to adhere to these 
regimens. Therefore, in many cases the treatment relies almost entirely on the use of 
pharmaceutical agents. In this regard, there are two categories of the most commonly used drugs. 
The first focuses on increasing insulin sensitivity in the peripheral organs using drugs such as 
roziglitazone, pioglitazone and metformin. The second drug category increases the output of 
insulin secretion in beta cells, with sulfonylureas being the most frequently used. Although these 
medications are the conventional line of treatment, they are not able to provide the precise 
metabolic regulation needed to avoid the complications associated with diabetes. Also, the 
success of these medications varies between patients, and their effectiveness in some cases is 
only temporary. Furthermore, many of these drugs have several associated risks, which can 
include fluid retention, lactic acidosis, increased cardiovascular risk as well as dangerous 
episodes of hypoglycemia (Inzucchi et al., 2015). 
 
Beta cell development 
Pancreas 
The pancreas is an organ that plays a critical role in the metabolic homeostasis of the body, and 
as discussed above, plays a major role in T1D and T2D. The pancreas is comprised of three main 
compartments: the exocrine and ductal tissues that are responsible for secreting digestive 
enzymes into the gut; and the endocrine compartment that is comprised of the islets of 
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Langerhans, which secrete hormones into the blood stream. The adult islet contains four 
endocrine cell populations, each secreting a unique hormone with an individual function. Beta 
cells secrete insulin, which drives glucose uptake in peripheral tissues and decreases renal and 
hepatic glucose production. Alpha cells secrete glucagon, a hormone that increases the blood 
glucose levels by stimulating hepatic glycogenolysis and gluconeogenesis (Quesada et al., 2008). 
Delta cells secrete somatostatin, a hormone found to potentially inhibit insulin and glucagon 
secretion (Hauge-Evans et al., 2009). Finally, PP cells secrete pancreatic polypeptide, a hormone 
associated with food intake regulation (Katsuura et al., 2002).         
 
In mice, the insulin-producing beta cells are found at the core of the islet, surrounded by the 
delta, alpha and pancreatic polypeptide cells (Shih et al., 2013). In contrast, human islet 
architecture has been intensely debated. Recently, Bonner-Weir revisited this subject using novel 
technologies and found that surprisingly, small islets resemble the rodent architectural pattern; 
however, larger islets consist of subunits of cell clusters of aggregates that nevertheless also 
contain a mantle-core arrangement (Bonner-Weir et al., 2015). The effect that such differences 
might have in the overall regulation of metabolism will need to be further explored. 
 
Pancreas development and beta cell differentiation  
The pancreas begins to form during mouse fetal development around embryonic day (e)8.5, with 
the evagination of the two epithelial buds that arise from the foregut endoderm. These buds 
expand and merge at e12.5, during a stage referred to as the primary transition. At this stage of 
development, the pancreatic epithelial buds predominantly contain multipotent pancreatic 
progenitor cells.  
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These pancreatic progenitor cells will give rise to the tip and trunk domain, marking the first 
lineage commitment and the secondary transition. The trunk cells will give rise to the endocrine 
and ductal lineage and the tip will form the acinar cells. During this transition, a population of 
cells from the trunk will start expressing Neurogenin (Ngn3), which marks the onset of 
endocrine differentiation; cells that do not express Ngn3 contribute to the ductal fate. The Ngn3-
expressing endocrine precursors will undergo dynamic changes in gene expression, 
independently giving rise to the five endocrine cell types: alpha, beta, delta, epsilon and PP cells 
(Figure 1-1) (Shih et al., 2013).   
 
Studies in mice have successfully mapped the overlapping of expression patterns of many 
transcription factors found to be important for pancreas development, and beta cell 
differentiation and maturation. In humans, limited information exists about the earliest stages of 
pancreas specification from the foregut endoderm. However, early development of the PDX1 
expressing pancreatic buds is comparable to rodents, nevertheless a primary transition stage has 
not been characterized. During subsequent stages, the transcription factor gene expression 
pattern between these two species has been found to be very similar. For example, the expression 
of PDX1, NGN3, NEUROD1 and NKX2.2 has been found to be just as important in human 
endocrine and beta cell lineage commitment as it is in rodents (Flanagan et al., 2014; Pinney et 
al., 2011; Piper et al., 2004; Rubio-Cabezas et al., 2010; Stoffers et al., 1997; Thomas et al., 
2009; Wang et al., 2006). Interestingly, one particular difference in regard to the timing of 
expression applies to NKX2.2; which appears to be absent from the progenitor population in 
humans, and instead appears after the induction of NGN3, at the initial maturation stage 
(Jennings et al., 2013; Jennings et al., 2015; Lyttle et al., 2008).   
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An interesting feature found in human islets, was the existence of polyhormonal cells during the 
majority of the islet developmental process. These polyhormonal cells were observed to resolve 
over time, establishing the appearance of monohormonal functional cells as an important step in 
maturation (Bocian-Sobkowska et al., 1999). The specific factors or mechanisms involved in this 
maturation step as well as in helping maintain a monohormonal identity are still unresolved. 
 
The comparative analysis between mouse and human pancreatic development has provided 
useful information. However, the limited access to human samples has hampered progress. 
Alternative approaches to find factors or signals that are involved or can potentially promote beta 
cell maturation in humans are being developed. In the meantime, significantly valuable 
information has mostly been acquired from studies performed in rodents.  
 
Stem cells 
As discussed above, the current treatments for diabetes are only able to manage symptoms, and 
haven’t yet been able to prevent or reverse the disease. Presently, there are major efforts focused 
on providing a renewable supply of healthy and functional beta cells. Stem cell research has 
made great strides in accomplishing this goal.  Stem cells represent ideal candidates for 
generating surrogate beta cells, due to their special capacity to grow almost indefinitely and their 
ability to give rise to cells from the three germ layers, including pancreatic islets (Thomson et al., 
1998; Yu et al., 2007).  The first attempts to differentiate human embryonic stem cells into 
insulin producing cells resulted in the differentiation of a limited number of insulin expressing 
cells.  
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Even though this was a significant achievement, the efficiency and secretory capacity of the cells 
was very limited. Additionally, most of the insulin expressing cells co-expressed other islet 
endocrine hormones, highlighting their immature state (Assady et al., 2001; Blyszczuk et al., 
2003; Segev et al., 2004).  
 
Subsequent studies focused their efforts at improving the differentiation process, mainly by 
recapitulating the different stages of beta cell development during embryogenesis.  Through this 
approach, the efficiency of the protocol was increased, achieving a greater number of insulin 
expressing cells, albeit still with limited secretory response (Jiang et al., 2007; Kroon et al., 
2008). In 2014, Pagliuca and colleagues (Pagliuca et al., 2014), as well Rezania and colleagues 
(Rezania et al., 2014) simultaneously optimized the differentiation process, obtaining cells that 
more closely resembled human beta cells. These cells expressed important markers of beta cell 
function and identity and were able to secrete insulin at levels that closely resemble human beta 
cells.  
 
Generation of higher quality beta-like cells represents a milestone in the field, and holds great 
promise for the development of future therapies, patient disease modeling and drug screening.  
There are still important limitations to be considered, such as the immune system response to 
these cells. This concern may possibly be addressed by using the patient’s own cells through the 
differentiation of induced pluripotent stem cells. In the case of T1D, novel encapsulation 
technologies are being developed to protect the surrogate beta cells from the immune system 




One caveat of in vitro differentiation protocols is their variable efficiency: they tend to yield an 
estimated 10-30% of cells with beta cell characteristics, a small population of polyhormonal cells 
and a large population of undifferentiated cells. These results raise important points to consider. 
First, there appears to be heterogeneity within the population of differentiated cells, which results 
in one population being more responsive to the signals during the differentiation process. 
Second, beta cell identity and metabolic maturation has not been completely achieved yet, as 
compared to human beta cells. These are important issues, not only with regards to the 
physiological importance of a stable functional identity, but also to prevent the development of 
teratoma formation. Therefore, it will be essential to acquire more information on the factors and 
signaling pathways that help induce the final steps of the maturation process and lock beta cells 
into their identity, so that we can efficiently differentiate insulin-producing beta cells that acquire 
and retain their function over time and post-transplantation.  
 
Beta cell maturation 
The maturation stage represents an important step in the differentiation process of the beta cell, 
and establishes the cell’s glucose sensing ability and fully developed metabolic function.  This 
process has become an area of great interest in the last decade, due to the difficulties associated 
with differentiating fully functional beta cells from embryonic stem cells (ESCs). Although there 
has been some success, as described above, the correct and efficient functional maturation of 






The most important process during the functional maturation of a beta cell is the acquisition of 
tightly regulated glucose stimulated insulin secretion (GSIS). 
Traditionally, GSIS has been defined as the differential insulin secretion response between low 
(2.8mM) and high (> 10mM) glucose concentrations.  Studies in rodents have consistently found 
that in the early postnatal period, beta cells secrete high basal levels of insulin at low glucose 
concentrations, and have a blunted insulin response when stimulated with a higher glucose 
concentration (Blum et al., 2012; Boschero et al., 1988; Freinkel et al., 1984). Furthermore, it has 
also been observed that beta cells during the neonatal period contain fewer insulin granules 
compared to mature cells. As beta cells mature, their glucose response evolves such that they 
secrete basal insulin at low glucose concentrations, and enhance their insulin secretion in 
response to higher glucose levels. This results in efficient glycemic regulation and prevention of 
hypoglycemia.  
 
During the early postnatal period, important epigenetic changes in histone methylation have been 
found to set the stage for subsequent maturation. More specifically, genes involved in the 
activation of the glycolytic flux at low glucose levels have been found to become highly 
methylated during this period. They include: Hexokinase 1 (Hk1), hexokinase 2 (Hk2), lactate 
dehydrogenase A (Ldha), as well as aldolase B fructose-biphosphate (AldoB)(Dhawan et al., 
2015). Concomitantly, these enzymes are expressed during development and subsequently 
become repressed as the cell continues to mature. Repression of this gene program ensures that 
pyruvate is shuttled into the tricarboxilic acid cycle (TCA) cycle, and therefore couples blood 
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glucose levels with proper insulin secretion.  These enzymes have previously been categorized as 
islet disallowed genes, which are genes specifically repressed in beta cells compared to other 
tissues.  Accumulating evidence has shown that in general, repression of disallowed genes is 
necessary for proper beta cell function (Pullen et al., 2010; Thorrez et al., 2011). Furthermore, 
their negative regulation has been shown to take place through active repression (Thorrez et al., 
2011). In this regard, de-novo DNA methyltransferase 3a (DNMT3a) has been found to be 
responsible for the initiation of methylation of important regulatory regions in these genes 
(Dhawan et al., 2015). However, DNMT3a expression also decreases overtime, suggesting that 
active repression of such genes must be enforced by other independent factors or mechanisms. 
 
Transcription factors involved in beta cell development have also been implicated in the 
acquisition of beta cell maturation. Neurod1, a transcription factor critical for insulin expression 
and beta cell differentiation, was also found to play an important role during maturation. In 
support of this, mice devoid of Neurod1 expression have a defective response to glucose, 
accompanied by the expression of glycolytic genes and Ldha. Furthermore, the beta cell gene 
expression profile in these mice was found to be comparable to immature neonatal beta cells (Gu 
et al., 2010). Additional factors involved in beta cell maturation are MafA, a transcription factor 
that becomes active right after birth, and Tshz1 a recently discovered maturation factor. Deletion 
of either factor renders mice with significant glucose intolerance due to beta cell maturation 
defects and defective insulin secretion (Hang et al., 2014; Raum et al., 2015). Although these 
factors have been found to be important for the establishment of beta cell maturation, more 
information is needed on the mechanisms employed and the signals that regulate them.   
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It has recently become more evident that beta cell insulin secretory function continues to develop 
beyond 3 weeks of age. At this stage, basal insulin secretion is further reduced and insulin 
secretion response to high glucose concentrations is enhanced. Recent studies have found that 
maternal weaning represents an important event in furthering such improvements. The transition 
from a high fat diet to a high carbohydrate diet was found to be the most influential 
factor(Jacovetti et al., 2015; Stolovich-Rain et al., 2015).  Interestingly, additional studies have 
implicated microRNAs in the maturation of beta cells during such transition. Global expression 
analysis during this period revealed significant microRNA expression changes. Furthermore, 
when expression of these microRNAs was mimicked in newborn beta cells, premature GSIS was 
acquired. However, when these microRNAs were inversely modified in the adult stage, a 
reversion of GSIS to an immature state was not attained (Jacovetti et al., 2015). This highlights 
the absolute importance that context and timing have in the maturation process.  
 
There have been important attempts to find markers of maturation that help in the development 
of beta cell differentiation protocols. In this regard, Ucn3 is one of such markers that becomes 
highly expressed during the early maturation stage (Blum et al., 2012). Although it cannot induce 
maturation on its own, it was recently found to be co-secreted with insulin to function as a 
potentiator of somatostatin release, causing insulin inhibition and better glycemic control (van 
der Meulen et al., 2015).   
 
Overall, functional maturation appears to be acquired in several consecutive stages.  Evidence 
suggests that factors and signals both in the environment and at the molecular level play very 
specific and controlled functions in this process.  
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There is a pressing need for more information that helps identify those factors and their 
mechanisms. Such information will be very valuable in the optimization of beta cell 
differentiation protocols, as well as in other alternative therapies. 
 
Beta cell function 
Insulin biosynthesis and secretion 
The most important functional feature of the beta cell is its ability to secrete insulin in a tightly 
regulated manner in response to the body’s metabolic demands. Insulin is a peptide hormone 
whose primary function is to regulate the blood glucose levels by promoting glucose uptake in 
several organs of the body.  
 Insulin is first translated as pre-proinsulin, and is then transported across the rough endoplasmic 
reticulum in the lumen where it is cleaved, giving rise to its product proinsulin (Chan et al., 
1976; Patzelt et al., 1978).  After acquiring three-disulfide bonds that allows it to properly fold, 
proinsulin moves to the Golgi and into immature secretory granules; where it is cleaved into 
insulin and C-peptide by the pro-hormone convertases Pcsk1 (PC1) and Pcsk2 (PC2). The end 
product insulin is then stored in mature secretory granules (Huang and Arvan, 1995; Itoh et al., 
1996; Kemmler et al., 1972; Malide et al., 1995) 
 
There are different molecules that can stimulate insulin secretion, such as the glucagon-like-
peptide 1 (GLP-1), gastric inhibitory polypeptide (GIP), cholecystokinin (CCK), peptide YY 
(PYY) and oxyntomodulin. However, the main potentiator for insulin secretion is glucose 
(Poitout et al., 2006). In rodents, glucose is identified and transported into the beta cell through 
the Glut2 transporter (McCulloch et al., 2011; Thorens et al., 1988).  
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Subsequently, glucose is phosphorylated by the rate limiting enzyme glucokinase. This enzyme 
is a member of the hexokinase family; its low affinity for glucose allows it to continuously 
control insulin secretion with a threshold that falls within normal glucose levels (Xu et al., 1995). 
Although glucose-6-phosphate (G6P) can be metabolized through a different mechanism, the 
predominant route for insulin secretion involves G-6-P incorporation into the glycolytic pathway.  
The pyruvate end product of glycolysis is then oxidized in the mitochondria through the TCA 
cycle, resulting in increased cellular ratios of free adenosine triphosphate (ATP) to adenosine 
diphosphate (ADP) (Kennedy et al., 1999). This process ultimately leads to closure of the K+ 
(KATP) channels that results in membrane depolarization (Ashcroft et al., 1984; Cook and Hales, 
1984).  Voltage gated calcium channels then open to trigger the fusion of insulin granules with 
the membrane, releasing insulin (Yang and Berggren, 2006).   
 
Maintenance of beta cell identity 
Throughout the endocrine differentiation process, a combination of signals and regulatory 
mechanisms elegantly outline and shape what will become the identity of the functional beta cell. 
It was previously believed that this process was strictly unidirectional, giving rise to cells with an 
irreversibly  “locked” identity. However, important breakthroughs such as the ability to 
reprogram differentiated cells into pluripotent stem cells by the introduction of key factors have 
shown otherwise (Takahashi and Yamanaka, 2006). Therefore, it has become more evident that a 
sufficient level of plasticity remains in the differentiated cell, and that active regulation must 
exist in order to maintain its functional identity. Finding the factors and underlying mechanisms 
that maintain such identity has become a main priority, due to their important implications in the 
therapies that are currently under development.  
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Although a big gap of information still exists in this area, several studies have begun to show the 
implication of developmental transcription factors in the maintenance of adult beta cell identity 
and function.  
 
Transcription factors 
Loss of function studies have started to shed light on the different roles that these factors play in 
the adult stage of the beta cell, as well as the consequences that result when this regulation is 
disturbed. For example, one of the main outcomes observed when beta cell identity is lost is the 
absence of hormone expression.  
In this regard, Talchai and colleagues (Talchai et al., 2012) showed that loss FoxO1 during 
stressful conditions caused loss of insulin expression in a big population of islet beta cells. These 
cells were found to de-differentiate to a progenitor like state, as shown by the expression of 
progenitor markers that included: Ngn3, Oct4, Nanog and L-Myc. Furthermore, a portion of 
these cells were found to express other islet endocrine hormones such as somatostatin, pancreatic 
polypeptide and glucagon. Interestingly, no co-expression of insulin and these other hormones 
was found, further supporting that in this case de-differentiation to a progenitor state must 
happen in order to acquire these other endocrine identities.  
 
Similarly, loss of identity followed by the expression of other islet endocrine hormones such as 
glucagon or somatostatin has also been found after the loss of Grg3, Nkx6.1 and Pdx1(Gao et al., 
2014; Metzger et al., 2014; Taylor et al., 2013).  However, unlike the FoxO1 mutant beta cells, 
these cells did not regress to a progenitor state, as shown by the absence of progenitor markers.  
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Instead this cells co-expressed insulin with either glucagon or somatostatin, therefore exhibiting 
a partial trans-differentiation.  These findings highlight the versatility of the beta cell, capable of 
responding in different ways according to the different circumstances. 
Although these cells were able to co-express these other hormones, it is unknown whether those 
new identities were completely functional.  
 
Another important outcome that commonly occurs when beta cell identity is perturbed is the up-
regulation of the disallowed genes.  Ldha, AldoB, Hk1, Hk2 and Pcx are some of the genes that 
most frequently become dysregulated. Due to their inherent characteristics and functions, their 
up-regulation is translated into a dysregulated GSIS response that in some cases resembles the 
one found in immature beta cells. This particular response has consistently been found in loss of 
function studies of Neurod1, MafA, Insm1 and Rfx6 (Gu et al., 2010; Jia et al., 2015; Nishimura 
et al., 2015; Piccand et al., 2014). Of these factors, Rfx6 was shown to be a critical regulator of 
this gene program. Loss of this transcription factor resulted in the significant up-regulation of 54 
of 68 disallowed genes (Piccand et al., 2014).   
 
Ultimately, loss of functional identity results in glucose intolerance and rapid progression to 
diabetes. These findings show that functional features acquired during the maturation stage, such 
as the repression of disallowed genes and of other alternative identities, also have to be actively 
maintained during the adult stage.  Interestingly, even though the aforementioned transcription 
factors have shown both specific and independent functions; the ablation of their expression 
consistently results in the dysregulation of overlapping targets. This overlap can be explained by 
the formation of transcription factor complexes, where different combinations of these factors 
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serve to regulate specific gene programs. Evidence for this combinatorial network formation was 
brought by Pasquali and colleagues (Pasquali et al., 2014) through a detailed analysis of mapped 
chromatin states, DNA binding sites of key beta cell transcription factors, as well as gene 
expression profiles specific for human islets.  Remarkably, it was shown that this novel 
regulation of islet specific gene expression by clusters of transcription factors was done through 
enhancer binding. In this regard, NKX2.2, PDX1, NKX6.1, MAFB and FOXA2 were found to 
directly bind these enhancer regions. Additionally, these enhancers were enriched for motifs that 
are recognized by HNF1a, RFX, FOXA, NEUROD and MAFA.  
Further confirmation of this kind of network regulation was recently provided by a loss of 
function study of Insm1 in mouse beta cells (Jia et al., 2015). Loss of this factor resulted in beta 
cells reversing to an immature state, with essential beta cell function genes becoming 
dysregulated. Most importantly, regulatory regions associated with such targets genes were 
found to be cooperatively bound by Insm1, Neurod1 and Foxa2.  
 
Epigenetic regulatory mechanisms 
The mechanisms employed by transcription factors to induce and maintain beta cell identity are 
still largely unknown. However, it has become more evident that such factors can interact with 
specific chromatin regulators in order to influence the epigenetic landscape and ultimately 
regulate gene expression. Recent findings have demonstrated the importance that chromatin 
modifications play in the development and acquisition of functional identity in beta cells. In this 
regard, it was shown that prior to lineage induction, pioneer factors such as FOXA1 and FOXA2 
open the chromatin and bind to enhancers that then become poised by acquiring the H3k4me 
chromatin mark.  
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This priming of enhancers allows subsequent binding of lineage determinant factors in a 
stepwise manner (Wang et al., 2015). Ultimately, these epigenetic modifications pave the way 
for the acquisition of different endocrine lineages.  
Several of these epigenetic marks have been intensely studied in the beta cell, which is the case 
of H3k27me3; a chromatin mark associated with repression. Arensberguen and colleagues (van 
Arensbergen et al., 2010) found that H3k27me3 arises de novo during beta cell differentiation in 
a very tissue specific manner. It was shown to repress regulators of inappropriate cell fates such 
as neural, skeletal and heart development. Additionally, it actively repressed genes that were 
detrimental for proper beta cell function during the adult stage, therefore maintaining its 
functional identity. In support of these findings, several disallowed genes that are actively 
repressed during adulthood are also marked by H3k27me3 (Thorrez et al., 2011). Furthermore, 
Pasquali and colleagues (Pasquali et al., 2014) found that many of the enhancers associated with 
beta cell function and identity, posses not only repression (H3k27me3) chromatin marks but also 
marks associated with activation (H3k27Ac) and priming (H3k4me).  
 
Disruption of these chromatin marks has been shown to have very deleterious effects in gene 
programs important for beta cell identity. In support of this, histone deacetylase (HDAC) 
inhibitors caused dysregulation of the insulin secretion pathway when applied to BTC3 cells. 
Interestingly, two classes of HDAC inhibitors were used in this study. The first class made of 
hydroxamic acids, which inhibited HDAC1, HDAC2, HDAC3, HDAC6 and HDAC8 caused the 
down-regulation of important beta cell regulators that included Nkx6.1, Nkx2.2, Pdx1 and 
Neurod1. The second class, composed of orthoamino anilides, which inhibits HDAC1, HDAC2 
and HDAC3, resulted in the increase of alpha cell regulators such as MafB and Arx.  
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In turn, this resulted in the significant up-regulation of glucagon expression in these cells 
(Kubicek et al., 2012).  
 
Overall, it is becoming more evident that epigenetic marks play a very important role in 
preserving the functional identity of beta cells. During the differentiation process, it is likely that 
epigenetic marks are involved in the assembly of transcription factors complexes but also in their 
reinforcement too. This can be inferred from the different outcomes obtained when transcription 
factors are deleted at different stages of life. It is possible that the subsequent activation of other 
factors and further conformational rearrangement of such complexes renders their original 
function in them, redundant at a later stage.  
 
Nevertheless, it has become clear that during the adult stage, epigenetic chromatin marks still 
need to be actively maintained in order to preserve beta cell identity and function. It relation to 
this, several transcription factors can interact with chromatin remodeler complexes and regulate 
gene expression. A recent study found Pdx1 to interact with the Swi/Snf chromatin remodeler. 
Interestingly, the activation or repression activities of this factor were mediated by its core 
components, Brg1 and Brm respectively. Binding to either one of these components was 
influenced by environmental signals, allowing for a dual and dynamic response (McKenna et al., 
2015). Even though such kinds of interactions have started to be found for other transcription 
factors such as Isl1 and Nkx2.2, more information is needed to understand this kind of regulation 
(Papizan et al., 2011; Wang et al., 2016).   
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Loss of identity in beta cells, apart from causing disturbed functional features can also initiates 
events such as dedifferentiation or even direct reprogramming to other different identities. This 
ability to acquire other identities when a transcription factor is lost raises two important points, 
the inherent plasticity still conserved in the adult stage, and the existence of factors that guard the 
identity of the beta cell by tightly regulating such plasticity. Furthermore, the identities acquired 
by beta cells commonly pertain to the islet endocrine lineage. Bramswig and colleagues 
(Bramswig et al., 2013) found that in humans, a large fraction of genes important for beta cell 
function and identity were bivalently marked  (H3k4me3+/H3k27me3+) in the adult stage in 
other cell pancreatic types, particularly alpha cells. These surprising results show that plasticity 
exists in the endocrine islet populations, and the similarities in the chromatin landscape allows 
them to interconvert under certain circumstances. Understanding how these factors and their 
regulation of the epigenetic landscape influences these events will be of great importance in the 
development of future diabetes therapies.  
 
Loss of beta cell identity during disease 
Loss of beta cell identity during disease conditions has been found in mouse models of diabetes, 
including the insulin resistant GIRKO and the db/db mice. Here, beta cell loss of identity leads to 
dedifferentiation, and it is accompanied by a decrease in beta cell markers that include MafA, 
Nkx6.1 and Pdx1 (Guo et al., 2013; Talchai et al., 2012). The extent of beta cell de-
differentiation is positively correlated with the degree of hyperglycemia.  
 
In humans, evidence has been found for the loss of beta cell identity in T1D and T2D patients. 
Novel findings have shown that during T1D, in addition to beta cell apoptosis due to the immune 
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system attack, beta cells can undergo a process of neogenesis from alpha cells, which is then 
followed by trans-differentiation into delta cells. Here, T1D patients show an increase in delta 
cells that correlates as a direct function with the duration of the disease. Cells co-expressing 
insulin with somatostatin as well as insulin with glucagon were consistently found. Additionally, 
cells co-expressing insulin and somatostatin were found to express NKX6.1, further supporting 
that trans-differentiation between the beta and delta cell lineage was taking place. Interestingly, 
the amount of co-expressing cells varied greatly between patients, with some patients presenting 
islets where all the insulin expressing cells co-expressed somatostatin (Piran et al., 2014). More 
patient samples will be needed to assess the frequency of this event in this population, and most 
importantly the signals that influence those changes in cell identity. 
 
Loss of beta cell identity in T2D has also been confirmed in several studies. Islets from T2D 
patients present a significant increase population of cells that contain no endocrine hormone 
expression. Due to the fact that these cells contain mislocalized expression of important beta cell 
factors such as NKX6.1, FOXO1 and MAFA, it is likely that these cells were once beta cells that 
have now lost their identity. Interestingly, co-expression of NKX6.1 and somatostatin was found 
in a population of cells in these patients. These findings could potentially imply that these cells 
have not only lost their identity but have also gained a different endocrine identity. It is unlikely 
that this population of cells is functional; nonetheless that remains to be confirmed.   
In contrasts to findings from diabetes mouse models, no expression of progenitor markers has 
been found so far in these cells, which could be the result of mechanistic differences between 
these two different species (Guo et al., 2013; Talchai et al., 2012).  
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Lastly, beta cell partial trans-differentiation has also been observed in these patients, with cells 
co-expressing insulin-glucagon as well as insulin-somatostatin (White et al., 2013; Yoneda et al., 
2013). 
 
Overall, these studies demonstrate the critical role that beta cell identity plays during 
pathophysiological conditions. Whether it has a causative role in the development of diabetes, 
and or  influences its progression remains to be determined. Furthermore, the nature of the 
signals, and how they render beta cell transcription factors dysfunctional and unable to maintain 
its identity is still unresolved. In this thesis work, I will focus on a transcription factor named 
Nkx2.2, which I have found to be essential for the maturation and maintenance of beta cell 
identity and function; and whose function points to be conserved in mice and humans.  
 
Nkx2.2 
Nkx2.2 is part of the NK2 homeodomain transcription factor gene family that was first identified 
in Drosophila. This factor contains 273 aminoacids and contains three protein domains: the 
tinman domain (TN), the homeodomain (HD) and the NK2 specific domain (SD). All of these 
domains posses conserved homology, and among them the homeodomain is responsible for 
binding DNA (Kim and Nirenberg, 1989). There are five other members in the NK2 family that 
have been identified in mice: Nkx2.1, Nkx2.3, Nkx2.4, Nkx2.5 and Nkx2.6. 
Several of them have been shown to have important functions in the specification and regulation 
of cell fate decisions in a variety of organs (Caprioli et al., 2011; Czompoly et al., 2011; Du et 
al., 2008).  
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Nkx2.2 is found in the intestine, the central nervous system and the pancreas (Arnes et al., 2012). 
Within the pancreas, Nkx2.2 is first expressed at the onset of pancreatic bud evagination, 
becoming overtime more restricted to the core in the endocrine precursors. Finally, in the mature 
islet, it is expressed in all of the beta cells, in the majority of the alpha and PP cells, and remains 
absent from the somatostatin expressing delta cells (Arnes et al., 2012; Sussel et al., 1998).  
 
In order to analyze Nkx2.2 developmental function within the pancreas, Sussel and colleagues 
(Sussel et al., 1998) deleted this factor in mice. Loss of Nkx2.2 caused overt hyperglycemia, 
resulting in mice dying shortly after birth. At the cellular level, deletion of this factor resulted in 
an ablation of the beta cell population, with an accompanying decrease in the alpha and PP cell 
populations. Interestingly, a population of cells that did not express any insulin, but that 
contained some	beta	cell	markers	remained.	It	was	proposed	at	the	time	that	loss	of	Nkx2.2	
had	arrested	the	beta	cell	population	in	an	undifferentiated	state.	However,	in	a	later	study	
Prado	 and	 colleagues	 (Prado	 et	 al.,	 2004)	 found	 that	 this	 cell	 population	 was	 in	 fact	
expressing	 ghrelin;	 a	 hormone	 associated	 with	 the	 regulation	 of	 food	 intake,	 which	 is	
expressed	 in	 several	 tissues	 including	 the	 brain	 and	 the	 stomach	 (Klok	 et	 al.,	 2007).	
Therefore,	 loss	 of	 Nkx2.2	 prompted	 an	 increase	 of	 the	 ghrelin	 cell	 population	 at	 the	
expense	of	 the	beta	cell	population.	Collectively,	 these findings showed that Nkx2.2 plays a 
critical part during pancreas development, and more specifically in specifying the beta cell 
population. 
 
In humans, it was recently found that NKX2.2 plays a comparatively important function during 
development. Patients with homozygous null mutations of NKX2.2 presented with very similar 
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phenotypes as the ones observed in the Nkx2.2 null mice. These patients had defects in insulin 
secretion, diabetes at an early age with no evident exocrine dysfunction, as well as affected 
motor and intellectual functions (Flanagan et al., 2014). The similarity in the phenotypes of both 
of these species suggests a conservation of function of this factor during development.  
 
To address the mechanism behind the function of Nkx2.2 in the developing pancreas, Doyle and 
colleagues used an Nkx2.2 dominant activator or repressor derivative under the Pdx1 promoter 
as a substitution for endogenous Nkx2.2 in the mouse developing islets.  Although no significant 
effect was found with the Nkx2.2-activator derivative, the Nkx2.2-repressor was able to partially 
rescue the Nkx2.2-null phenotype previously observed in the pancreas. There was a full recovery 
of the alpha cell population, a decrease in the ghrelin population, and a recovery of a small 
number of beta cells. Although these cells expressed insulin, they did not express Glut2 and 
MafA, which are important beta cell markers acquired during the maturation stage (Doyle et al., 
2007). These results showed that Nkx2.2 repressor activity during differentiation serves to 
specify the alpha cell population, and to suppress the ghrelin lineage. However, its inability to 
fully rescue the beta cell population, and activate maturation markers pointed to a possible 
activator function during the maturation and adult stage.  
 
The activator function of Nkx2.2 and its ability to regulate the mature beta cell was tested using a 
transgenic mouse line that expressed the Nkx2.2-repressor in the presence of endogenous 
Nkx2.2. These mice became severely diabetic at weaning and presented with disrupted islet 
architecture, a decrease in maturation factors, and a dysregulated beta cell function (Doyle and 
Sussel, 2007).  
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These important findings showed that Nkx2.2 is likely to function both as repressor and as an 
activator, and is required not only during development but also during the adult stage of the beta 
cell.  This dual function has been observed in the drosophila orthologue of Nkx2.2, where the 
nature of its molecular interactions allows it to function as an activator or a repressor (Yu et al., 
2005).  Furthermore, Papizan and colleagues (Papizan et al., 2011)  found that Nkx2.2, through 
its TN domain can interact with factors such as DNMT3a, Grg3 and HDAC1 and form a 
repressive complex that silences the Arx promoter. Interestingly, mutations in this domain not 
only perturb beta cell differentiation but also cause beta to alpha cell trans-differentiation.  
 
Overall, these results highlight the essential function that Nkx2.2 plays during beta cell 
development, and provide evidence for a possible differential function of equal importance in the 
maturation and maintenance of the adult beta cell identity. This function had not been able to be 
explored due to the lethality of the Nkx2.2-null phenotype. However, using an Nkx2.2 
conditional allele (Mastracci et al., 2013), I have deleted Nkx2.2 specifically in beta cells during 
the maturation stage as well as during the adult stage. This thesis work aims to address the 
requirement of Nkx2.2 function once the beta cell has differentiated. Furthermore, it will explore 
the regulatory mechanisms behind this function and the main targets involved. 
 
In humans, it has been shown that NKX2.2 binds to enhancers associated with beta cell specific 
gene targets; such genes have been associated with islet cell identity and function.  
Additionally, it has also been revealed that enhancers bound by NKX2.2 in these cells, contain 
single nucleotide polymorphisms associated with T2D (Pasquali et al., 2014).   
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To evaluate the possible involvement of NKX2.2 in the human adult beta cell, I deleted this 
factor using a sh-NKX2.2 adenovirus and assessed the expression changes of its aforementioned 
targets. This thesis will present evidence for a conservation of function in the maintenance of 





Figure 1-1: Pancreatic Endocrine Development. Figure adapted from (Shih et al., 2013) 
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Chapter 2 
Maintenance of pancreatic beta cell identity requires active repression of non-
beta cell endocrine genes 
 
Lori Sussel conceived the mouse study. Giselle Dominguez Gutierrez and Teresa L. Mastracci 
collected and analyzed the mouse data. Giselle Dominguez Gutierrez conceived and executed the 
human islet study. Aaron Bender assisted with the human islet studies. Vincenzo Cirulli 
performed the EM studies and assisted with their interpretation. Aristotelis Tsirigos assisted with 
the computational analysis of ChIP-Seq and RNA-Seq data. Klaus H. Kaestner provided the raw 
data for the mouse chromatin marks for comparative analysis. Lori Sussel and Giselle 
Dominguez Gutierrez assembled and analyzed the data and wrote the manuscript.  
  
Introduction 
Type 1 and Type 2 diabetes mellitus (T1D and T2D) are chronic conditions in which glycemic 
control becomes severely dysregulated. Although there are many causes of diabetes, one of the 
main contributors to the progression of disease is the loss of beta cell function and beta cell mass, 
which ultimately leads to an inability to meet metabolic demand (Prentki and Nolan, 2006). 
Recently, Talchai et al. (2012) proposed that loss of beta cell identity rather than beta cell death 
accounted for a significant portion of the beta cell loss reported during diabetes progression. This 
landmark study raised the possibility that permanent regulatory mechanisms must be sustained to 
maintain the fully differentiated functional state of the beta cell.  
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Therefore, understanding the mechanisms required to actively maintain beta cell identity during 
adverse metabolic conditions that could lead to diabetes will be essential for the development of 
interventions and/or therapies to treat the disease. 
 
Studies from many labs have identified the extrinsic signaling pathways and intrinsic 
transcriptional networks needed to generate functional insulin producing beta cells in vitro and in 
vivo (reviewed in (Pan and Wright, 2011). More recently, there has been increasing evidence that 
several of the developmental regulatory factors that are essential for endocrine lineage 
specification, including Nkx6.1, NeuroD1 and Rfx6, are also required for the maintenance of 
beta cell function in the adult (Schaffer et al., 2013); (Taylor et al., 2013); (Naya et al., 
1997);(Gu et al., 2010);(Smith et al., 2010);(Piccand et al., 2014). This suggests that many of the 
transcriptional regulatory networks that are necessary for the initial specification of beta cells 
may continue to be expressed in the adult beta cell to actively maintain beta cell identity and 
function. 
 
Nkx2.2 is a highly conserved homeobox transcription factor that has been shown to be a critical 
regulator of cell fate decisions in the pancreas, intestine and central nervous system (Sussel et al., 
1998); (Prado et al., 2004); (Desai et al., 2008);(Anderson et al., 2009);(Papizan et al., 
2011);(Mastracci et al., 2011);(Clark et al., 2014);(Zhu et al., 2014). During embryogenesis, 
Nkx2.2 is expressed throughout the developing pancreatic epithelium and gradually becomes 
restricted to the Neurogenin3 (Ngn3)–expressing endocrine progenitor population, and 
subsequently to the alpha, beta, PP and epsilon cell lineages (Arnes et al., 2012).  Within the 
adult islet, Nkx2.2 expression is maintained in the alpha, beta and PP cells.  
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Global deletion of Nkx2.2 in mice demonstrated that Nkx2.2 is essential for endocrine lineage 
specification; deletion of Nkx2.2 resulted in decreased formation of alpha and PP cells, as well as 
a complete abrogation of beta cell specification, leading to severe hyperglycemia and neonatal 
lethality (Prado et al., 2004);(Sussel et al., 1998). In humans, loss of function mutations in 
NKX2.2 also resulted in the development of permanent neonatal diabetes, suggesting that 
NKX2.2 is also important for beta cell formation during human fetal development (Flanagan et 
al., 2014). 
 
Although these studies demonstrated a critical role for Nkx2.2 in beta cell development in mice 
and humans, the complete absence of beta cells precluded assessment of its function in adult 
islets. To determine whether Nkx2.2 is necessary for beta cell maturation and/or function, we 
generated mouse models that allowed constitutive and inducible deletion of the Nkx2.2 gene. 
Disruption of Nkx2.2 in maturing beta cells resulted in the rapid development of diabetes, with a 
significant decrease in insulin expression and content. Strikingly, the loss of genes associated 
with beta cell identity and function was accompanied by an increase in the expression of genes 
from alternative islet cell fates.  Furthermore, beta cells appeared to trans-differentiate to acquire 
other non-beta cell endocrine identities. Deletion of Nkx2.2 in fully differentiated adult beta cells 
also resulted in the very rapid onset of diabetes and the islets of these mice were also 
characterized by a loss of beta cell identity and the acquisition of alternative endocrine cell 
characteristics, confirming the importance of Nkx2.2 in both establishing and maintaining beta 
cell identity. These results demonstrate that Nkx2.2 is a master regulator that plays a critical role 
in mouse and human beta cells to maintain beta cell identity and function in the adult by directly 
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Materials and Methods 
Mouse Strains 
Mice carrying a conditional allele of Nkx2.2fl/fl (Mastracci et al., 2013) were bred to the RIP:Cre 
mice (Herrera, 2000) and to the tamoxifen inducible MIP-CreERT mice (Wicksteed et al., 2010). 
To induce the MIP-CreERT allele, tamoxifen (Sigma) was dissolved in corn oil, and a dose of 
100mg/kg body weight was given via intraperitoneal injection every other day for 3 days. All 
mice used in physiologic tests were male, unless otherwise stated in the text. 
 
Tissue Preparation and Immunohistochemistry  
Mouse pancreata was fixed for either 2 hours or overnight in 10% neutral-buffered formalin 
(VWR) at 4°C.  Tissue was then transferred to 70% ethanol and subsequently embedded in 
paraffin and sectioned at 5 µm thickness. Antigen retrieval was performed using 10mM sodium 
citrate buffer pH=6 at boiling temperature in a water bath for 15 min. After a 20 min cool down 
period at room temperature, samples were incubated with primary antibodies overnight and 
further stained with secondary antibodies the following day. Details of primary and secondary 
antibodies utilized are listed in Tables 2-1 and 2-2 respectively.  
 
Transmitted Electron Microscopy (TEM) 
Ultra structural analysis of wild type and Nkx2.2 mutant pancreatic islets was performed by 
transmitted electron microscopy (TEM), as previously described with minor modifications 
(Miller et al., 2008; Diaferia et al., 2013). Briefly, islets were fixed immediately after isolation at 
4°C in 0.1M sodium cacodylate buffer pH=7.4, 2% paraformaldehyde, 2.5% glutaraldehyde 
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(Electron Microscopy Sciences (Fort Washington, PA), and 3 µM CaCl2. Samples were then 
post-fixed with osmium tetraoxide (1% (w/v) in H2O) and counterstained with uranyl acetate 
(2% (w/v) in H2O). Following gradual dehydration in ethanol, samples were embedded in 
Durcupan resin (Sigma Immunochemicals) and polymerized overnight at 60°C and –20mm Hg, 
as described (Staubli, 1963). Ultrathin sections (70 nm) were then cut using a 35° angle Diatome 
diamond knife, and mounted on 300 mesh gold grids (Electron Microscopy Sciences, Fort 
Washington, PA). Following counterstaining with uranyl acetate (1% (w/v) in H2O) and Sato 
lead [1% (w/v) in H2O] sections were imaged at 80 keV using an electron microscope (JEOL 
JEM-1400, Akashima, Japan), equipped with a Gatan Ultrascan 1000XP with 2K x 2K resolution 
CCD camera, using the image acquisition software Gatan Digital Micrograph (Gatan, Inc.  
Pleasanton, CA).  
 
Chromatin Immunoprecipitation and Sequencing 
MIN6 cells were grown to confluency in a 15 cm culture dish and were formaldehyde-cross-
linked for 10 min. Cross-linked chromatin was fragmented by sonication using the Diagenode 
BioRuptor for 3 cycles of 5min each (30 sec on/off). Two micrograms of rabbit anti-Nkx2.2 
antiserum was added to 80 µg of sheared chromatin. The antibody/chromatin complex was left to 
rotate end-to-end overnight at 4°C, and subsequently pulled with protein G Dynabeads (Fisher). 
Chromatin was washed, eluted and reversed cross-linked, followed by protease treatment.  
 
ChIP-seq libraries were prepared as per instructions of the Kapa Hyper Prep kit for Illumina.  
Sequencing was performed using the Illumina HiSeq 2500 system as per manufacture’s 
instructions.  
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 Peak annotation was performed using the MACS peak caller (version 1.4.2 20120305). The q-
value cutoff we used was 0.05.  Binding peaks were annotated with genes with a transcription 
start site present within 100kb of an identified Nkx2.2 binding peak. De novo motif analysis was 
performed with Hypergeometric Optimization of Motif EnRichment (HOMER v4.6).  GEO 
Accession number# GSE79725. 
 
Western Blot Analysis 
Pancreatic islets were isolated out from approximately 21week old mice. Protein was extracted 
using RIPA (Radio-Immunoprecipitation Assay) buffer during a 5 min sonication period (30sec 
on/off). 13µg of protein were used for analysis as previously described (Borok et al; 2015). 
Primary and secondary antibodies used are listed in Table 2-1 and 2-2 respectively.   
 
Glucose Tolerance Test, Plasma Insulin and Insulin Content 
Glucose tolerance tests: Mice were fasted overnight, followed by an intraperitoneal injection 
with glucose (2mg/g body weight). Tail vein blood samples were collected at several time-points 
after the injection. Glucose concentration was determined using the Accu-Chek Compact Plus 
Blood Glucose Meter.  
Acute plasma insulin assays: Mice were fasted overnight, followed by intraperitoneal injections 
with glucose (2mg/g body weight). Blood plasma samples were collected at different time-points 
after the injection through heart puncture, and individual cohorts were used per time-point. 
Plasma insulin was measured by ultrasensitive insulin ELISA kit (Crystal Chem).  
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Pancreatic insulin content: pancreata was dissected and disrupted using a homogenizer. Insulin 
was extracted by acid ethanol. The insulin concentration was analyzed by insulin ELISA 
(Mercodia) and normalized to pancreas weight (gm).  
 
Islet Isolation and Glucose Stimulated Insulin Secretion Assays (GSIS) 
Mouse pancreatic islets were isolated by perfusing the pancreata with Collagenase P (Roche) 
through the common hepatic bile duct at a concentration of 1mg/ml of M199 medium 
(Invitrogen). Pancreata was removed and dissociated at 37°C for 16 min. After several washes 
using M199 medium supplemented with 10% FBS (Gemini Bio Products), islets were separated 
onto a gradient using a combination of serum free M199 medium and Histopaque (Sigma). Islets 
were then handpicked to avoid exocrine contamination and processed for different applications.   
 
Human islets from 3 donors were obtained through the NIH-supported Integrated Islet 
Distribution Program (IIDP) via Mt Sinai Human Islet Core facility. The islets were harvested 
from deceased donors without any identifying information at NIH-approved centers with 
informed consent and IRB approval at the islet-isolation centers. Donors ranged in age from 32-
64 years old (mean 45.7); two were females and one was a male. Mean BMI was 28.03 (range 
23-32.8).  
 
GSIS assays: 20 islets/well were cultured in Kreb’s buffer with a glucose concentration of 
2.8mM for one hour in a 12 well plate, supernatant was collected to measure basal insulin 
secretion. Islets were then transferred to Kreb’s buffer with 16.7mM glucose, and the 
supernantant was collected after one hour.  
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Islets were disrupted using a homogenizer in 50 ul of lysis buffer (150mM NaCl, 50mM Tris-
HCL [pH8.0], 1% IGEPAL), and insulin content was extracted by acid ethanol. Insulin in 
supernatant and islet lysates was measured by ultrasensitive insulin ELISA (CrystalChem). 
Secreted insulin was calculated as percentage of total insulin content per hour. 
 
Quantitative Real Time RT-PCR and RNA-Seq 
Total mRNA was prepared from P0 pancreata or isolated islets at 4 weeks of age using the 
RNAEasy micro kit (Qiagen) and reverse transcribed with Superscript (Roche). Real time RT-
PCR was carried out with either SYBR Green (Bio-Rad) or Taqman probes (Applied 
Biosystems) and measured on a BioRad CFX96 Real Time System. Expression levels were 
normalized to Cyclophilin b for mouse samples and to 36B4 for human samples. Primers and 
probes are listed in tables 2-3 and 2-4 respectively.  
 
For RNA-Seq analysis, RNA from mouse and human islets was obtained using the RNEasy 
micro kit (Qiagen). RNA quantity and quality was assessed using the Agilent 2100 Bioanalyzer 
and 400ng of total RNA were sent to the Columbia University Genome Center for library 
preparation, sequencing (Illumina 2500) and bioinformatics analysis. Expression changes were 
considered significant if they had a p value of at least 0.05 and a log2 fold change of at least 0.5.  
GEO Accession number# GSE79725. 
 
Adenovirus 
Ad.shRNA directed against human Nkx2.2, targeting GCCGACGAGTCACCGGACAA was 
obtained from Welgen Inc.  
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Ad.Scrambled was provided by Dr. Andrew Stewart (Icahn School of Medicine at Mount Sinai). 
Adenovirus were packaged and produced in HEK-293A cells. Titers were determined by plaque 
assay (PFU). Dispersed human islets were transduced with either experimental or control 
(Ad.Scrambled) at 100 and 300 MOI in serum free media for 2 hrs. Transduction was terminated 
by adding complete medium containing 10% FCS and cultured for 96 hrs. 
 
Cell Lines 
The adenovirus packaging cell line, HEK-293A (Life Technologies), was cultured in DMEM 
medium supplemented with 10% FCS, and 1% penicillin- streptomycin, and 1X MEM 
containing non-essential amino acids. The MIN6 cell line was cultured in DMEM medium 
supplemented with 10%FBS and 1% penicillin- streptomycin. 
 
Morphometric analysis 
For all morphometric analysis, quantification was done on 6 evenly spaced sections through the 
whole pancreas. To determine beta cell mass and islet number, tiles of each of these sections 
were taken at 10X using a Leica fluorescent microscope (DM5500). To calculate beta cell mass, 
each section was stained with insulin (beta cell area) and amylase (pancreas area). Islet area was 
divided by the pancreas area and then multiplied by the weight of the pancreas (gms). To 
determine the islet number, all islets were quantified in each section and then divided by the 
pancreas area (cm2).  To determine the amount of insulin cells per islet area as well as the 
percent of polyhormonal cells, images of 5 islets per section in all 6 levels were captured at 40X 
on a Zeiss Confocal LSM 710 microscope.  
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Percent of polyhormonal cells was calculated by dividing the insulin positive cells by the cells 
co-positive for insulin and either somatostatin, glucagon or pancreatic polypeptide and multiplied 
by 100. To determine the insulin cells per islet area, insulin positive cells were counted and 
divided by the islet area. At least 3000 cells were counted to calculate insulin cells per islet area, 
and at least 3500 for the percent of polyhormonal cells. All areas and cell quantification were 
processed with Image J 1.46R software   
 
Image Analysis 




Statistical analysis was calculated using a 2-tailed Student’s unpaired t test. Results are expressed 
























































































Deletion of Nkx2.2 in beta cells causes glucose intolerance and impaired insulin secretion  
To determine the function of Nkx2.2 specifically in beta cells, we generated RIP:Cre; Nkx2.2fl/fl 
(hereafter referred to as Nkx2.2ΔBeta) mice (Herrera, 2000) (Mastracci et al., 2013).  For the 
metabolic studies, we included cohorts of mice carrying each single allele as controls to ensure 
these individual mutations were not contributing to the observed metabolic defects (Figure 2-1). 
Nkx2.2ΔBeta mice displayed efficient deletion of Nkx2.2; greater than 80% of the Nkx2.2 RNA 
transcript was deleted in the insulin-producing cells of four week old Nkx2.2ΔBeta mice versus 
littermate controls (Figure 2-1A). Western blot analysis confirmed there was a corresponding 
reduction of Nkx2.2 protein (Figure 2-1B). Since Nkx2.2 is also expressed in several islet 
endocrine cell populations, we used co-immunofluorescence staining for Nkx2.2 and insulin in 
adult islets to demonstrate the efficient recombination of Nkx2.2 specifically in the beta cell 
lineage (Figures 2-1C-D). 
 
 In contrast to the Nkx2.2 null mice, which develop severe hyperglycemia and die shortly after 
birth (Sussel et al., 1998), both female and male Nkx2.2ΔBeta mice survive into adulthood. The 
adult mice appear overtly indistinguishable from their littermate controls (data not shown) and 
exhibit no apparent difference in body weight (Figure 2-2A-B). However, by three weeks of age, 
the male Nkx2.2ΔBeta mice displayed significantly higher blood glucose levels than controls. The 
hyperglycemic phenotype became exacerbated with age, reaching mean glucose levels of 339.3 
mg/dL at 11 weeks (Figure 2-1E). Fasting blood glucose levels in the Nkx2.2ΔBeta mice was also 
significantly elevated (≥ 217.3 mg/dL) at 11 weeks of age (Figure 2-1F), indicating their 
progression to diabetes. 
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Consistent with the elevated ad libitum and fasting blood glucose levels, three week old 
Nkx2.2ΔBeta mice were unable to effectively clear a glucose bolus (Figure 2-1G). The metabolic 
impairment worsened with age, suggesting there was a progressive loss of beta cell function in 
Nkx2.2ΔBeta mice (Figure 2-1H). Similar phenotypes were observed in female Nkx2.2ΔBeta mice, 
however, hyperglycemia and glucose intolerance were manifested at slightly older ages and with 
less intensity (Figure 2-2C-D).  To eliminate the possibility that the observed glucose intolerance 
was due to an inability of the peripheral tissues to take up glucose, we performed an insulin 
tolerance test at 3 weeks of age. As expected for a beta cell-specific genetic modification, no 
difference in insulin resistance was detected between Nkx2.2ΔBeta mice and controls (Figure 2-
2E). 
 
Nkx2.2ΔBeta mice display reduced numbers of insulin-producing cells 
Consistent with previous studies demonstrating that Nkx2.2 directly regulates insulin expression 
(Cissell et al., 2003), beta cell deletion of Nkx2.2 resulted in a significant reduction of insulin 
gene expression and total insulin content in four week old Nkx2.2ΔBeta mice (Figure 2-3A-B). 
Furthermore, there was a 33.6% decrease in beta cell mass in the Nkx2.2ΔBeta mice compared to 
their littermate controls (Figure 2-3C). Surprisingly, however, despite the large reduction in beta 
cell mass, there was no significant difference in the number of islets or islet size (Figure 2-3D-
E). A loss of insulin content without a corresponding change in islet size could suggest the 
retention of a beta cell population that no longer produced insulin. To explore this possibility, we 
introduced to R26R:Tomato allele into the Nkx2.2ΔBeta mice to genetically label the beta cell 
lineage regardless of its insulin-producing status.  
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Interestingly, although the Tomato reporter was co-expressed with insulin in the majority of 
control beta cells, the Nkx2.2ΔBeta mice contained a significant number of Tomato-expressing 
cells that had little or no detectable insulin expression (Figure 2-3F-G). This observation was 
validated by quantitative determination of the pixel intensity of insulin-specific 
immunoreactivity that revealed a significant reduction in the median distribution of pixel 
brightness in the Nkx2.2ΔBeta islets (Figure 2-3H-I). Furthermore, enumeration of the number of 
insulin-expressing cells per islet area confirmed the loss of insulin without a corresponding 
reduction in islet cell numbers (Figure 2-3J), suggesting that a loss of insulin content per cell and 
not cell loss causes the observed decrease in beta cell mass.   
 
Although the Nkx2.2ΔBeta mice display a significant reduction in the number of insulin producing 
cells, this degree of beta cell loss does not usually result in hyperglycemia (Peshavaria et al., 
2006); (Liu et al., 2000). To determine whether islet function was affected, we performed a GSIS 
on young and old Nkx2.2ΔBeta mice. Surprisingly, although these islets contain significantly less 
insulin-producing cells, they were able to secrete a higher percentage of insulin during a one-
hour glucose challenge in vitro (Figure 2-2F). However, the ability of Nkx2.2ΔBeta islets to secrete 
insulin declined with age (data not shown). This phenomenon has been previously observed in 
obese models of diabetes, such as the diabetic obese/obese (ob/ob) mouse, where an increased 
GSIS occurs as an adaptation to an increased insulin demand and obesity, which is thought to 
represent a pre-diabetic state (Irles et al., 2015). Although the Nkx2.2ΔBeta islets are able to 
compensate in response to a single dose of glucose in vitro, they are unable to mount an insulin 
response to an in vivo glucose challenge (Figure 2-3K), indicating the Nkx2.2ΔBeta mutant beta 
cells can only mount a transient response to glucose and are metabolically dysfunctional.  
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Nkx2.2 is essential for the acquisition of monohormonal beta cell identity 
To identify the primary molecular changes that were causing beta cell dysfunction after deletion 
of Nkx2.2, we assessed the transcriptome of isolated islets extracted from Nkx2.2ΔBeta mice and 
their littermate controls at 4 weeks of age. This analysis was performed shortly after the onset of 
hyperglycemia to minimize secondary affects caused by a chronically impaired metabolic 
environment. Consistent with the observed beta cell dysfunction, we found several essential beta 
cell genes, including those encoding beta cell transcription factors, glucose transporter 2 (glut2), 
insulin granule proteins and components of the insulin secretory pathway to be significantly 
down-regulated (Figure 2-4A). We validated a subset of these gene changes in islets at the 
protein level, including the loss of two of the most functionally important beta cell factors, Glut2 
and Nkx6.1 (Figure 2-5). Notably, in addition to the loss of many essential beta cell genes in the 
Nkx2.2ΔBeta mice, there was a significant up-regulation of the non-beta cell pancreatic endocrine 
hormones, including somatostatin, pancreatic polypeptide and glucagon (Figure 2-4A). Since we 
had not observed an overall increase in islet size that could account for increased numbers of 
non-beta endocrine cells that would express these hormones, we immunostained islets with 
insulin and somatostatin, pancreatic polypeptide or glucagon to determine their cell localization. 
In addition, we lineage traced the mutant beta cells using the R26R:Tomato reporter to assess 
whether the beta cell population in the Nkx2.2ΔBeta mice had acquired expression of the non-beta 
cell endocrine hormones and/or novel cellular identities. This analysis revealed that not only 
were the Nkx2.2ΔBeta islets losing beta cell gene expression, but a significant number of beta cells 
were co-expressing insulin and either glucagon, pancreatic polypeptide or somatostatin.  
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In addition, there were populations of lineage-labeled beta cells that appeared to be completely 
reprogrammed; they no longer expressed insulin, but now expressed an alternative endocrine 
hormone (Figures 2-4B-K). These data revealed that loss of Nkx2.2 is sufficient to cause partial 
and/or complete trans-differentiation of beta cells into the other islet cell types.  
 
Quantification of the bihormonal and polyhormonal populations at 4 weeks of age revealed that 
approximately 10% of the beta cells had acquired multi-hormonal features (Figure 2-4L-N). 
Detailed immunofluorescence analysis of the Nkx2.2ΔBeta mutant islets also revealed 
extraordinary heterogeneity in the Nkx2.2ΔBeta islets.  At any given age, we observed constant 
relative ratios of Tomato lineage-labeled beta cells that were expressing only insulin, expressing 
no insulin, expressing insulin with other hormones and expressing other endocrine hormones 
without insulin (Figure 2-4K). Interestingly, we did not observe evidence of beta cell 
dedifferentiation; Ngn3, Sox9 or other progenitor markers were not upregulated in the beta cell 
lineage (data not shown). To further characterize the different beta cell populations at the single 
cell level, electron microscopy was performed on control and Nkx2.2ΔBeta mutant islets. As 
predicted by the light microscopic analysis, control islets contained endocrine cells displaying 
insulin granules with characteristic electron-dense crystal cores (Figure 2-4O and data not 
shown). In contrast, the mutant islets were filled with beta cells containing both insulin granules 
and either glucagon or somatostatin-like granules (Figure 2-4P,Q). Remarkably, these results 
suggest that many of the Nkx2.2ΔBeta beta cells have acquired a fully hybrid identity that is 
characterized not only by the expression of more than one endocrine hormone, but also by the 
likely expression of their corresponding granule packaging machineries.  There were also a large 
number of cells that were devoid of granules and displayed features of altered endoplasmic 
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reticulum (ER) with numerous enlarged cisternae (Figure 2-4R and Figure 2-6, B and C, red 
stroked arrows), whose membranes exhibited reduced ribosome content and increased frequency 
of free ribosomes in the cytosol (Figure 2-6, C, blue stroked arrows). Many beta cells from 
Nkx2.2ΔBeta mice also contained insulin granules that exhibited an altered crystallization pattern 
(Figure 2-6, D, red stroked arrows), and numerous coalescent granules (D, inset, arrowheads), 
suggesting early stages of increased secretory vesicle autophagy. Collectively, these 
ultrastructural alterations indicate that in the absence of Nkx2.2, many of the beta cells became 
severely dysfunctional.  It was not possible to determine whether these cells derived from the 
polyhormonal populations or arise independently. Surprisingly, despite the high degree of 
observed beta cell dysmorphogenesis and apparent dysfunction, there was little evidence of beta 
cell death by Caspase3 staining (data not shown), which was consistent with the maintenance of 
normal islet size in the Nkx2.2ΔBeta mice (Figure 2-1E) and the preservation of wild type levels of 
Chromogranin A expression. 
 
Nkx2.2 directly activates beta cell genes and represses non beta cell features 
The transdifferentiation phenomenon observed in the Nkx2.2ΔBeta mice could be directly caused 
by the deletion of Nkx2.2 or could be secondary to the loss of beta cell identity. To distinguish 
these possibilities, we performed ChIP-Seq analysis in MIN6 cells to determine how Nkx2.2 
directly impacts the regulatory networks required to maintain beta cell identity. Similar to 
previous studies in human beta cells (Pasquali et al., 2014), Nkx2.2 predominantly bound distal 
intergenic regions of the genome, rather than at promoter elements (Figure 2-7A). De novo motif 
analysis showed CACTC to be the core motif sequence that is preferably bound by Nkx2.2 in 
46.42% of its targets (p<1e-217) (Figure 2-7B). 
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 Consistent with the Nkx2.2ΔBeta phenotype, Nkx2.2 binds and activates beta cell genes that are 
essential for glucose uptake and insulin secretion (Slc2a2, G6pc2, Ucn3, and Slc30a8), insulin 
granule homeostasis (Sytl4, Ptprn2, and Rab37) and key beta cell transcription factors (Nkx6.1, 
Insm1, and Tle3). Interestingly, Nkx2.2 was also found to directly bind and repress the non-beta 
cell endocrine genes, including the endocrine hormones (Sst, Ppy, Pyy, and Npy), islet disallowed 
genes (Oat, Acot7, and Higd1a), as well as the alpha and delta cell determination factors Arx and 
Hhex (Figure 2-7C-G). In agreement with previous studies that have suggested that Nkx2.2 
functions as an activator and repressor (Doyle and Sussel, 2007), this analysis revealed that 
within the beta cell, Nkx2.2 simultaneously activates beta cell gene programs and represses non-
beta cell programs. This data is consistent with the polyhormonal phenotype observed in the 
Nkx2.2ΔBeta mice and clarifies that Nkx2.2 maintains beta cell identity and function by directly 
activating beta cell genes and repressing non-beta cell endocrine genes.  
 
The ability of Nkx2.2 to function both as an activator and repressor in a single cell may be 
dependent on the underlying chromatin features present in the vicinity of Nkx2.2 binding. To 
characterize the regions that appeared to be activated or repressed by Nkx2.2, we compared the 
association of Nkx2.2 binding peaks with chromatin marks present in young islets (Avrahami et 
al., 2015). Interestingly, consistent with the relatively equal number of activated (49.2%) and 
repressed (50.8%) targets (Figure 2-8A), Nkx2.2 appeared to equally associate with active 
enhancers (H3K4me+ and H3K27ac+) and poised enhancers (H3K4me+, H3k27ac-, H3k27me3-
). Only a small number of Nkx2.2 bound regions were associated with repressive marks 
(H3k4me+ and H3k27e3+) (Figure 2-8B). This would suggest, not unexpectedly, that Nkx2.2 
binds to active enhancers to regulate the expression of beta cell-specific genes.  
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However, it also suggests that Nkx2.2 function is equally necessary to maintain repression of the 
lineage-related non-beta cell endocrine genes that are associated with poised enhancers that have 
been implicated in facilitating islet cell plasticity (Wang et al., 2015). 
 
Nkx2.2 maintains beta cell function and identity in mature beta cells 
Although analysis of the Nkx2.2ΔBeta mice was performed in adult mice, it is possible that 
constitutive deletion of Nkx2.2 in the beta cells during their normal maturation process 
compromises the initial acquisition and “locking in” of a stable beta cell identity. To assess the 
importance of Nkx2.2 in maintaining beta cell function and identity not only during the 
maturation process of the beta cell but also after they have fully differentiated, we deleted Nkx2.2 
in adult beta cells. Adult Nkx2.2fl/fl; MIP-CreERT (Wicksteed, 2010) (hereafter referred to as 
Nkx2.2ΔAdultBeta) mice were administered intraperitoneal injections of tamoxifen every other day 
for five days. (Figure 2-9A). We were able to consistently achieve ~77% deletion of Nkx2.2 
mRNA from the treated mice (Figure 2-9B).                      
 
Interestingly, depletion of Nkx2.2 in the adult beta cell resulted in the very rapid onset of 
diabetes.  Ad libitum blood glucose levels of Nkx2.2ΔAdultBeta mice were significantly increased 
within 1 week of the last injection, and continued to worsen with age (Figure 2-9C). 
Correspondingly, a significant increase in the fasting blood glucose levels was observed; 
although, similar to the Nkx2.2ΔBeta mice (Figure 2-1F), this increase occurred at a slightly later 
stage (Figure 2-9D).  Furthermore, the Nkx2.2ΔAdultBeta mice were unable to effectively clear 
glucose following a glucose challenge (Figure 2-9E). This phenotype also became more severe 
with age (Figure 2-9F).  
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To investigate whether the observed islet dysfunction in the Nkx2.2ΔAdultBeta mice was also due to 
the development of polyhormonal cells, we introduced the R26R:Tomato reporter to lineage trace 
the beta cell lineage and immunostained the mutant islets with insulin and either glucagon, 
somatostatin or pancreatic polypeptide. Surprisingly, we were only able to identify cells co-
expressing insulin and somatostatin (Figure 2-9G-I); however, there were no cells co-expressing 
insulin and the other endocrine hormones (data not shown). These data suggest that Nkx2.2 is 
essential in the acquisition and maintenance of beta cell identity, during development and in the 
adult. However, it also implies that the level of beta cell plasticity becomes more restricted with 
age, and only retains the ability to acquire delta cell characteristics. 
 
Nkx2.2 function is maintained in human islets 
To investigate whether NKX2.2 is also important for the function and identity of human beta 
cells, islets from three individuals were infected with adenovirus encoding an shRNA directed 
against human NKX2.2 or a scrambled shRNA control. We were able to achieve an ∼80% 
reduction in NKX2.2 expression, which led to significant (p<0.05) gene expression changes of 
which approximately 38% were down-regulated and ~62% were up-regulated (Figure 2-10A). 
Comparison of the gene expression changes with previously published ChIP-Seq analysis of 
NKX2.2 binding sites in human islets (Pasquali et al., 2014) demonstrated that, similar to mouse 
Nkx2.2, human NKX2.2 functions both as an activator and repressor.  Notably, several important 
NKX2.2 gene targets were conserved, including NKX6.1, which was bound and down-regulated 
(Figure 2-10C) and SOMATOSTATIN, which was bound and up-regulated after loss of NKX2.2 
(Figure 2-10D).  
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Collectively, these data demonstrate that a conserved role for NKX2.2 in maintaining beta cell 
function and identity by activating important beta cell genes and actively repressing non beta 























There is increasing evidence that loss of beta cell identity and the acquisition of bihormonal and 
polyhormonal cells is occurring in the islets of patients with T1D and T2D (White et al., 2013) 
(Yoneda et al., 2013); (Piran et al., 2014). However, the molecular basis of these reprogramming 
events have not been elucidated, and it is not known whether these events participate in the 
initiation of disease or represent a condition that is secondary to disease progression. In the 
present study, we uncover the essential role of Nkx2.2 in the maturation and maintenance of 
adult mouse and human beta cell function and identity. Beta cell deletion of Nkx2.2 destabilized 
the beta cell phenotype, leading to a reduction in insulin expression and content, and the loss of 
some beta cell functional features (Figure 2-3A-C), which unexpectedly was not accompanied by 
cell death. Instead, we observed the presence of at least four different beta cells subpopulations 
within the mutant islets (Figure 2-4B-J): 1. Single positive insulin expressing cells; 2. Beta cells 
that co-express insulin and other islet hormones, suggesting the occurrence of a partial trans-
differentiation event; 3. Cells that have lost insulin expression and only express other islet 
endocrine hormones, perhaps indicative of a complete cellular trans-differentiation; and 4. Cells 
which did not express any hormones. The existence of these different beta cell populations 
suggests that beta cells could gradually traverse stepwise through partial reprogramming, then to 
complete trans-differentiation, and finally to a complete loss of beta cell identity (Figure 2-11). 
However, we did not observe changes in the relative ratios of these four different subpopulations 
with age or pregnancy, perhaps suggesting that the islet contains heterogeneous beta cell 
populations that differentially respond to the loss of Nkx2.2. We cannot, however, rule out the 




In contrast to previous studies that have shown beta cells undergo de-differentiation prior to 
reprogramming (Talchai et al., 2012), we did not observe significant increase in the expression 
of progenitor markers to suggest deletion of Nkx2.2 causes beta cell de-differentiation. Instead, 
our data suggests that loss of Nkx2.2 results in direct reprogramming by the primary regulation of 
specific gene sets. Interestingly, we also observed more restricted reprogramming potential in 
adult versus young beta cells. Deletion of Nkx2.2 in beta cells shortly after the activation of 
insulin, resulted in all combinations of polyhormonal cell populations; however, deletion of 
Nkx2.2 in adult beta cells only led to the formation of insulin and somatostatin co-expressing 
cells (Figure 2-9G-I), implying that the plasticity of the beta cell is diminished over time. The 
role of Nkx2.2 function in maintaining beta cell identity by activating beta cell gene programs 
and repressing non-beta cell programs appears to be conserved in human islets. Similar to loss of 
Nkx2.2 in adult mouse beta cells, inactivation of Nkx2.2 in human islets predominantly led to the 
up-regulation of SST (Figure 2-10D). Interestingly, the predominance of INS and SST co-
expressing cell populations has been described in several recent studies reporting the presence of 
polyhormonal cells in islets derived from diabetic individuals (Yoneda et al., 2013; Cinti et al., 
2016).  
 
In this study, we have determined that Nkx2.2 directly regulates beta cell function and identity. 
Although previous studies have demonstrated the ability of Nkx2.2 to function as an activator 
and repressor in certain cellular and genomic contexts, this is the first evidence that Nkx2.2 
simultaneously functions to directly activate the beta cell program and repress non-beta 
endocrine genes.  
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The unexpected finding that 47% of Nkx2.2 binding peaks were present at poised rather than 
repressed enhancers also provides an explanation for why beta cells are only able to revert to 
closely related endocrine cell fates, rather than a completely unrelated cell identity. Furthermore, 
it suggests a mechanism whereby Nkx2.2 is involved in the priming of enhancers during 
development and may be essential later for the direct activation of the genes involved in beta cell 
function as well as the active repression of gene sets that would otherwise activate non-beta islet 
related lineages.  Furthermore, the direct regulation of both beta cell and non-beta cell gene 
programs by Nkx2.2 suggests that presence of bihormonal and/or polyhormonal cells is not 
secondary to the loss of beta cell identity. Importantly, these studies also demonstrate the highly 
unstable nature of the beta cell; there is an ongoing need to actively maintain the activation of 
genes involved in beta cell function, but to also maintain repression of closely related gene 
programs.  Therefore, it is possible that in conditions of metabolic stress disruption of a single 
regulatory pathway will cause a simultaneous loss of beta cell function and identity. 
 
The development of polyhormonal cells during T1D and T2D has been postulated to be 
indicative of a more primitive endocrine cell phenotype that is known to exist during human islet 
cell development (Riopel et al., 2014). Interestingly, during the early stages of human pancreas 
formation, the endocrine cells are initially polyhormonal and only gradually resolve into 
monohormonal cell identities (Bocian-Sobkowska et al., 1999). Intriguingly, unlike in mouse 
pancreatic development where Nkx2.2 is expressed early and there are only minor populations of 
polyhormonal cells, in humans NKX2.2 is not detected until late in pancreas formation, during 
the stage when monohormonal cells are acquired (Jennings et al., 2013). This suggests that there 
may be an intrinsic function of Nkx2.2 for acquiring a functional monohormonal identity.   
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The role of Nkx2.2 in maintaining beta cell identity in T2D remains relatively unexplored.  
Whereas Nkx2.2 expression is down regulated more than 5 fold (padj < 1.19E-07) in Db/Db 
mouse islets and in primate models of diabetes induced by a high fat/sugar diet (Fiori et al., 
2013), Guo et al., (2013) did not detect changed expression levels of Nkx2.2 in samples from 
human patients with T2D. However, given the polygenic nature of T2D, it remains possible that 
larger sample sizes will identify NKX2.2 dysregulation in subclasses of T2D patients.  In support 
of this, Pasquali et al (2014) identified a large number of T2D SNPs present in islet enhancers 
that were occupied by NKX2.2. 
  
In summary, it is becoming increasingly clear that beta cell death may not be the primary cause 
of the loss of beta cell mass during diabetes progression. Instead, there is emerging evidence that 
fully differentiated mature beta cells in mice and humans retains much more plasticity than 
previously appreciated. In the present study, we identified Nkx2.2 as master regulator of such 
plasticity, actively repressing non-beta cell lineages and directly activating beta cell functional 
programs. Understanding the molecular mechanisms allowing for the retained plasticity will be 
important for deriving fully differentiated beta cells with a “locked-in” identity in vitro.  
Furthermore, these findings indicate that blocking or reversing beta cell reprogramming could 







Figure 2-1: Deletion of Nkx2.2 in beta cells results in diabetes  
 (A) qRT-PCR analysis of Nkx2.2 expression in islets isolated from Nkx2.2ΔBeta and control mice 
at 4 weeks of age (n=4). **p ≤0.01.  
(B) Western Blot analysis of isolated islets from Nkx2.2ΔBeta and control mice confirms a 
reduction of Nkx2.2 protein in islets isolated from four individual adult Nkx2.2ΔBeta mice.  
(C,D) Immunofluorescence staining of insulin (red) and Nkx2.2 (green) demonstrates the loss of 
Nkx2.2 expression in beta cells from Nkx2.2ΔBeta compared to control mice at 4 weeks of age.  
The white boxes indicate regions of the islet that are shown in higher magnification in C’ and D’. 
(E) Ad-libitum blood glucose levels in 3 week old male Nkx2.2ΔBeta mice compared to controls 
(n=5-22) and in 11 week old mice (n=6-18). **p≤0.01. Each control genotype was examined 
separately to ensure the individual Cre and floxed alleles did not cause metabolic phenotypes. 
(F) Higher fasting blood glucose levels are evident in 11 week old Nkx2.2ΔBeta mice compared to 
controls. (3 week old mice: n=6-23; 11 week old mice: n=8-21) *p≤0.05.  
(G) Glucose intolerance is observed in Nkx2.2ΔBeta male mice compared to controls at 3 weeks of 
age (n=6-23).  *p≤0.05; ***p≤0.001.  
(H) Glucose intolerance becomes more severe at 11 weeks of age in Nkx2.2ΔBeta male mice 















Figure 2-2: Development of diabetes is not influenced by changes in body weight or insulin 
sensitivity  
(A-B) No significant weight differences were found in Nkx2.2ΔBeta vs. littermate control females 
(n=5-20) and males (n=3-12). 
(C-D) Female Nkx2.2ΔBeta mice are glucose intolerant beginning at 3 weeks of age and become 
overtly diabetic by 11 weeks of age. *p≤0.05; **p≤0.01; ***p≤0.001. 
(E) Insulin tolerance tests demonstrate that the Nkx2.2ΔBeta mice do not have insulin sensitivity 
defects compared to controls at 3 weeks of age. (n=3-5). 
(F) Glucose stimulated insulin secretion assays demonstrate Nkx2.2ΔBeta mice are able to 




















Figure 2-3: Lineage tracing in Nkx2.2ΔBeta mice indicates loss of insulin expression in 
Nkx2.2ΔBeta beta cells  
(A) qPCR analysis of Insulin2 mRNA expression in islets from Nkx2.2ΔBeta mice compared to 
control mice at 4weeks of age (n=4). **p ≤0.01. 
(B)  There is a ~50% reduction in pancreas insulin content in Nkx2.2ΔBeta mice compared to 
control mice at 4 weeks of age (n=3). **p ≤0.01. 
(C)  Loss of Nkx2.2 results in decreased beta cell mass at 4 weeks of age (n=3). *p ≤0.05. 
(D)  There was no statistical difference found in islet numbers of Nkx2.2ΔBeta compared to 
control mice at 4 weeks of age (n=3). 
(E)  Islet size of Nkx2.2ΔBeta mice compared to control mice was not statistically different at 4 
weeks of age (n=3).  There was a trend down in the number of the largest islets, but the 
difference did not reach significance. 
(F,G) Immunofluorescence staining of insulin (green) and Tomato (red) shows a decrease or 
absence of insulin expression in tomato expressing beta cell lineages. White box indicates region 
magnified in G’ (with tomato channel) and G’’ (without tomato channel). 
(H, I) Digital quantification of insulin-specific immunoreactivity (Adobe Photoshop CS4).  
There is a significant reduction in the median distribution of the brightest pixels from a value of 
197 in control islets versus 68 in Nkx2.2ΔBeta islets. 
(J) Nkx2.2ΔBeta 4 week old mice have less insulin positive cells per islet area compared to 
controls (n=3).  ***p ≤0.001. 
(K)  Insulin levels are significantly lower in Nkx2.2ΔBeta mice after a glucose stimulus compared 






Figure 2-4: Nkx2.2 is essential for the establishment of beta cell identity 
(A) A subset of genes and their corresponding functional categories that were identified in RNA-
Seq analysis of islets isolated from Nkx2.2ΔBeta mice compared to controls at 4 weeks of age. 
Genes that are significantly up-regulated are indicated in green and significantly down-regulated 
genes are indicated in red.  All genes shown P≤0.05. The full dataset is available at 
GEO#GSE79725. 
(B-K) Immunofluorescence staining of pancreata from Nkx2.2ΔBeta and control mice at 4 weeks 
of age. White boxes indicate regions that are magnified in the panels in K. 
(B,E,H) Representative images of control islets co-labeled with insulin (green), Tomato (red) and 
either glucagon (B), pancreatic polypeptide (E) or somatostatin (H) (blue). 
(C,F,I) Representative images of Nkx2.2ΔBeta islets co-labeled tomato (red) and either glucagon 
(C), pancreatic polypeptide (F) or somatostatin (I) (blue). 
(D,G,J) Representative images of Nkx2.2ΔBeta islets co-labeled with insulin (green) and either 
glucagon (D), pancreatic polypeptide (G) or somatostatin (J) (blue). 
(K) Images of representative single lineage-labeled insulin-positive beta cells expressing either 
glucagon, pancreatic polypeptide, somatostatin and insulin-negative beta cells expressing either 
glucagon, pancreatic polypeptide, somatostatin.  The channels are separated out from left to 
right: glucagon, pancreatic polypeptide and somatostatin (blue), insulin (green) and tomato (red). 
The final column shows the merged channels.   
(L) Quantification analysis shows that an average of 10% of beta cells in Nkx2.2ΔBeta compared 
to control mice at 4 weeks of age co-express insulin and either glucagon, somatostatin or 
pancreatic polypeptide. 
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(M,N) Representative images showing immunofluorescence analysis of pancreata from 
Nkx2.2ΔBeta and control mice stained with guinea pig anti-insulin antibody (red) and a 
combination of the 3 rabbit anti-pancreatic polypeptide, rabbit anti-somatostatin and rabbit anti-
glucagon antibodies (green). 
(O-R) TEM of pancreatic islets reveals a combination of insulin and either glucagon or 
somatostatin-like granules in the same cell in Nkx2.2ΔBeta mice. Magenta lines outline individual 
beta cells. Granule identity is indicated by colored arrows: glucagon (blue), insulin (yellow) and 
somatostatin (green) (P,Q). Representative image of a beta cell from Nkx2.2ΔBeta islets with 














Figure 2-5: Loss of important beta cell protein expression in Nkx2.2ΔBeta islets 
correlated with their decreased RNA expression. 
(A-D) Representative images of immunostained islet sections from 4 week old (A,B) and 12 
week old (C,D) Nkx2.2ΔBeta mice (B,D) and their littermate controls (A,C).  Dapi (grey) marks 
the nuclei and Glut2 (green) is on the cell membrane.  Glut2 expression is decreased at 4 weeks 
of age and becomes almost undetectable at 12 weeks. 
(E-F) Representative images of immunostained islet sections from 4 week old Nkx2.2ΔBeta mice 
(E) and a littermate controls (F).  Insulin (blue), glucagon, somatostatin and pancreatic 
polypeptide, combined (red), and Nkx6.1 (green).  F’ and F’’ show higher magnification images 
of cells that are insulin+, express other hormones and are Nkx6.1 negative. 
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Figure 2-6: Nkx2.2ΔBeta islet cells exhibit ultra-structural alterations compatible with a 
disrupted secretory granules morphology and ER stress.  
(A-D) TEM images of single cells from control and Nkx2.2ΔBeta mice.  
(A) Representative image of normal-looking rough endoplasmic reticulum (RER) in control 
islets (arrowheads).  
(B,C) Islet cells from Nkx2.2ΔBeta mice show enlarged RER cisternae (red stroked arrows) and 
increased free ribosomes not associated with RER (blue stroked arrows).  
(D) Beta cells in Nkx2.2ΔBeta mice contained large populations of insulin granules that exhibited 


















Figure 2-7: Nkx2.2 directly activates important beta cell genes and actively represses non-
beta islet endocrine genes 
(A)  Distribution of regions bound by Nkx2.2 within the genome obtained from ChIP-Seq 
analysis performed in a MIN6 cell line (n=3). 
(B)  The consensus Nkx2.2 binding motif identified through de novo motif analysis. 
(C) Gene targets directly regulated by Nkx2.2 were identified by comparing the ChIP-Seq data 
with the RNA-Seq analysis from Nkx2.2ΔBeta vs. control adult islets. Bound and activated genes 
are indicated in red and bound and repressed genes are indicated in green. Full data set is 
available at GEO#GSE79725. 
(D-G) ChIP-Seq analysis identified binding of Nkx2.2 to active or repressed enhancers. qRT-
PCR analysis confirms differential expression of direct Nkx2.2 gene targets in islets from 





















Figure 2-8: Nkx2.2 activates and represses an equal amount of targets preferentially 
through active and poised enhancer binding 
(A) Comparative analysis of ChIP-Seq data from MIN6 cells with RNA-Seq data from 
Nkx2.2ΔBeta compared to control islets demonstrates that Nkx2.2 represses and activates 
relatively equal numbers of direct targets regulated by Nkx2.2.  
(B) Chromatin state of regions bound by Nkx2.2 shows preferential binding to active enhancers 
(H3k427ac+/H3k4me+) and poised enhancers (H3k4me+). Repressed enhancers 
(H3k4me+/H3k27me3+) constitute a minor proportion. ChIP-Seq analysis done using Nkx2.2 
binding peaks present in all triplicate samples.  
(C) De novo motif analysis of Nkx2.2 binding shows motifs and targets matched to other known 








Figure 2-9: Nkx2.2 is essential for the maintenance of beta cell identity and function in 
adult beta cells. 
(A) Schematic of tamoxifen treatment and experimental design. 
(B)  qRT-PCR analysis demonstrates significant deletion of Nkx2.2 in isolated islets from 
Nkx2.2ΔAdultBeta mice compared to control mice 5 weeks after the last injection (n=5-7). **p 
≤0.01. 
(C)  Deletion of Nkx2.2 increases ad libitum blood glucose levels in Nkx2.2ΔAdultBeta 
compared to control mice starting at 1 week after the last injection(n=16-20). * p≤0.05; **p = 
≤0.01; ***p ≤0.001. 
(D) Fasting blood glucose levels begin to be significantly increased 5weeks after the last 
injection in Nkx2.2ΔAdultBeta compared to control mice (n=12-15). * p ≤0.05. 
(E) Glucose tolerance tests indicate the Nkx2.2ΔAdultBeta are already glucose intolerant at 3 weeks 
after the last injection compared to control mice (n=12-15). **p ≤0.01; ***p ≤0.001. 
(F) Glucose intolerance becomes more severe 5 weeks after the last injection in Nkx2.2ΔAdultBeta 
compared to control mice (n=12-15).**p ≤0.01; ***p ≤0.001 
(G-I) Immunofluorescence staining of pancreata from Nkx2.2ΔAdultBeta and control mice 5 weeks 
after the last injection. Insets are magnifications of selected areas indicated by white boxes 















Figure 2-10:  NKX2.2 function is conserved in human islets 
(A) qRT-PCR analysis reveals significant deletion of NKX2.2 in human islets transduced with 
Ad.sh-NKX2.2 compared to scramble sh-RNA control vector (Ad.Scr) (n=3). *p≤0.05. 
(B) 1,114 genes were differentially regulated in human islets when NKX2.2 was reduced.  The 
graph indicates the percent distribution of genes differentially expressed (p≤0.05) from 
adenoviral mediated deletion of NKX2.2 in human islets compared to scramble control. 
(C-D) Binding sites shown to be activated/repressed in human islets through ChIP-Seq analysis 
show direct targets of NKX2.2 that become dysregulated after its deletion. Fold change values 

































Figure 2-11: Model of Nkx2.2 function in the adult beta cell 
Nkx2.2 appears to be a master regulatory protein that is essential for the acquisition and 
maintenance of beta cell identity. Loss of Nkx2.2 in beta cell results the formation of different 
beta cell subpopulations that were identified by the expression of the beta cell-specific tomato 
reporter: 
Dysfunctional β cells: This category includes lineage-labeled (red dots) insulin-expressing cells 
(purple dots) unable to mount a proper insulin response and represents the largest population of 
mutant beta cells. 
Polyhormonal β cells: Lineage labeled (red dots), insulin positive (purple dots) beta cells that are 
mis-expressing the other islet endocrine hormones (green dots).  It is possible that these cells 
represent incomplete transdifferentiation. 
Insulin- β cells: Lineage labeled (red dots) beta cells that have lost insulin expression, but have 
acquired the expression of other non-beta endocrine hormones (green dots). 
(Empty β	cells):	 A rarer population of lineage labeled cells (red dots) without expression of any 
endocrine hormones.  
It is unknown whether these populations originate independently or are able to introconvert. 









Conclusions and Future Perspectives 
 
Diabetes is a condition that has already reached epidemic proportions and there are millions of 
patients waiting for a cure. A very promising treatment approach is to identify a renewable 
source of beta cells either through replication or iPS cell differentiation. Another alternative is 
the development of therapies to stop and reverse the loss of beta cell functional features and 
identity that is associated with diabetes. To be able to achieve such a monumental goal, we need 
to gain a profound understanding of the factors and mechanisms that participate in the generation 
and maintenance of the beta cell. Furthermore, it is also of equal importance to understand what 
influences those factors and networks to cause them to become dysregulated and adopt a 
pathophysiologic state.  
 
In this thesis project, I focused on a transcription factor that had been found to be essential for 
beta cell differentiation during fetal development (Sussel et al., 1998), and that held great 
potential for maintaining a vital role during the adult stage of the beta cell as well. I utilized a 
variety of techniques to explore and understand how Nkx2.2 regulates beta cell function and 
identity. I discovered that Nkx2.2 is important for the maturation and maintenance of functional 
identity in beta cells, and it accomplishes this by actively repressing non beta cell endocrine 
features and simultaneously activating beta cell genes. These findings highlighted important 
dynamics governing beta cell identity and revealed new questions that point to new avenues of 
research that should be pursued in the future, both with regards to Nkx2.2 function and more 




During this thesis work I uncovered important roles for Nkx2.2 in the maturation and 
maintenance of function of the beta cell. Although we have acquired significant knowledge in 
this area, there is much more to understand about the beta cell and its regulation that will allow 
us to design effective therapies.  
 
Nkx2.2 regulation of the epigenetic landscape 
In my thesis studies, I discovered Nkx2.2 binds to enhancers of genes associated with beta cell 
function, as well as to genes regulating non beta cell endocrine identity (Figure 2-7C-G). These 
genes contained chromatin marks that have been found to represent a poised state, as well as 
activation and repression states. Previous studies have found that such chromatin marks are 
either acquired sequentially during differentiation of the cell lineage or during the maturation 
stage (Pasquali et al., 2014; Thorrez et al., 2011; van Arensbergen et al., 2010; Wang et al., 
2015). Furthermore, some of these marks seem to become more stable overtime, whereas others 
require active maintenance instead. It would be important to understand how is Nkx2.2 involved 
in the acquisition of such marks. To pursue this, I would knockdown Nkx2.2 in mice at different 
stages through the use of the MIPCreER inducible system. ChIP-Seq of these chromatin marks 
would be performed in isolated islets of these mice. This would allow for the determination of 
the time window when Nkx2.2 is needed to impart such regulation. Additionally, it would reveal 
the chromatin marks that Nkx2.2 is responsible to produce. Furthermore, it would shed light on 
the states in which Nkx2.2 is required to actively maintain beta cell function, and where Nkx2.2 
function becomes redundant once beta cell identity has been established. 
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 Finally, it has been found that genes important to maintain beta cell function and repress other 
endocrine identities are bivalently marked (H3k4me3+/H3k27me3+) indicating they are in a 
poised state. This bivalency has been suggested to explain why beta cells become reprogrammed 
to endocrine identities rather than taking on the identities of unrelated tissues such as heart, liver 
or intestine (Bramswig et al., 2013). The information gained from this study would provide 
important information on the association of such poised enhancers and the reprogramming of 
beta cells. 
 
Binding partners of Nkx2.2 
It is recognized that Nkx2.2 is expressed in pancreatic progenitors during development and that it 
becomes restricted to the beta, alpha and PP cell lineage as differentiation proceeds (Arnes et al., 
2012; Sussel et al., 1998). These cells, although close in proximity have very different identities 
and functions. The mechanism by which Nkx2.2 is able to impart differential regulation in these 
cell types is likely to be related to the co-factors that it binds. In support of this, Papizan and 
colleagues (Papizan et al., 2011) have shown that Nkx2.2 assembles a repressor complex in beta 
cells to repress the Arx promoter and therefore maintain the beta cell versus the alpha cell 
identity. In contrast, that same repressive complex is not found in the alpha cells, even though 
Nkx2.2 is present at that same region. 
 
Exploring the different transcription factors and chromatin remodeling complexes that partner 
with Nkx2.2 will be of great importance to further understand its regulatory functions in these 
different cell types. Results from the motif analysis that was performed from the Nkx2.2 ChIP-
Seq experiment showed a significantly larger percentage of the Nkx2.2 targets to be bound by 
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Neurod1, Rfx4/5/6, FoxO1 and Nkx6.1 (Figure 2-8C). Therefore, a detailed analysis of the 
overlapping in binding of these factors would offer important information as to which of them 
interact to assemble such complexes; as well as whether particular combinations of factors are 
specifically associated with activation or repression of gene targets. Furthermore, simultaneous 
or sequential binding of these different factors could be assessed using the novel re-ChIP 
technology. Finally, interaction confirmation of these factors could be accomplished by co-
immunoprecipitation analysis.  
 
Chromatin remodeler complexes are also critical in regulating the epigenetic landscape of the 
cell (Campbell and Hoffman, 2016).  Nkx2.2 has already been found to bind histone modifying 
factors such as DNA methyltransferases (Dnmt1 and Dnmt3a) as well as to the histone 
deacetylase 1 (HDAC1) (Levine, Manuscript in preparation; Papizan et al., 2011). Furthermore, 
a mass spectrometry analysis has already been performed in the laboratory, finding components 
of the NurD and B-Wich complexes to be bound to this factor as well (data not shown). 
Interestingly, a large proportion of the genes being repressed by Nkx2.2 contained the 
H3k27me3 mark (Figure 2-7F-G), which has been found to be conferred mostly by the PRC2 
complex (Simon and Kingston, 2013). Therefore, it is likely that this factor also interacts with 
this chromatin-remodeling complex as well. Correlation of the binding of the aforementioned 
complexes with the chromatin marks associated with Nkx2.2 targets warrants further 
examination. Of clinical importance, many of these epigenetic regulator components such as 
HDAC inhibitors are already being used in the clinical setting (Chan et al., 2016; Petrich and 
Nabhan, 2016). For this reason, analysis of the beta cell specific epigenetic regulatory 
mechanisms could offer viable options to more easily modify specific gene programs. 
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Post-translational regulation of Nkx2.2 
It has been convincingly demonstrated that Nkx2.2 is essential for beta cell differentiation 
(Sussel et al., 1998). In this thesis work I have provided evidence for its critical role in the 
functional maintenance of such differentiated state. A very important question that remains is 
what happens to this factor prior or during disease progression. Studies in diabetes mouse models 
such as the db/db mice show a significant decrease in the expression of Nkx2.2 (Dominguez, 
Romer and Sussel, data not shown). 
In humans, variable expression levels of Nkx2.2 are seen in samples from donors with T2D (data 
not shown). This variability is likely due to the small sample size used, which cannot account for 
disease duration and types of treatments applied.  Nevertheless, another very likely possibility 
apart from expression dysregulation is the acquisition of post-translational modifications as a 
response to environmental signals. Such type of regulation has been found to affect the function 
of other important beta cell transcription factors (Maganti et al., 2015; Rena et al., 2002).  
 
A former graduate student in the laboratory, James Papizan, has identified potential sites for such 
types of modifications in Nkx2.2.  To further explore this possibility, a mass spectrometry 
analysis could first be peformed in vitro using mouse and human beta cell lines during normal 
and challenging conditions; to identity the differential regulation of such residues. Once the most 
promising modifications were found, mutations in those sites could be introduced in order to 
assess their implication in co-factor and DNA binding as well as in epigenetic regulation.  
Identification of the enzymes and signaling pathways involved in the post translational regulation 
of Nkx2.2 could hold great promise for future therapies. 
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Loss of functional identity has been confirmed in patients with T1D and T2D (Piran et al., 2014; 
White et al., 2013; Yoneda et al., 2013). Furthermore, beta cell differentiation from iPS cells is 
still not quite able to mature those cells properly. We know that Nkx2.2 plays an important role 
in the maturation of the beta cells as well as in keeping them locked in that state.  
Overexpressing this factor in the last maturation step within the iPS beta cell differentiation 
protocol or in the clinical setting could be done trough viral infection. However, the potential 
dangerous effects render this approach only useful for its mechanistic study. Additionally, 
overexpressing this factor might not be enough to bring those cells to a functional mature state if 
it is not receiving the proper signals to guide it. To better approach these issues, finding the 
enzymes or compounds that could influence this factor in the proper manner could represent a 
more viable clinical option. 
 
Beta cell identity and function 
The findings of my studies have uncovered interesting features about the beta cell that include an 
enhanced plasticity, a surprising cellular heterogeneity as well as dynamic epigenetic landscape. 
Their potential influence in the regulation of beta cell function and identity, as well in the 
development and progression of diabetes merits their further understanding.  
 
Beta cell re-differentiation 
The unexpected cell plasticity found in this study, which was reflected in their partial or 
complete trans-differentiation into other endocrine identities, opened up exciting windows of 
opportunity. Due to the fact that beta cells can acquire other identity features, it is likely that they 
can also recover their identity if the disturbed main pathways are repaired and restored to normal 
	 86	
conditions again. The current treatments for diabetes mainly focus on inducing the beta cell to 
secrete more insulin to cope with the elevated blood glucose levels. This kind of approach only 
stresses the cell, and leads it to its own failure and demise.   However, there are efforts focusing 
on the possibility of re-differentiation of the beta cells; they range from insulin therapy to give 
the dedifferentiated and exhausted beta cells a rest, to the screening of chemical compounds 
libraries to find candidates that can reinstate mature beta cell identity again(Blum et al., 2014; 
Wang et al., 2014). It will be important to determine the timing and circumstances in which beta 
cells can be re-differentiated, as well as if prevention of identity loss is also an alternative. 
 
Importance of enhancer regulatory complexes in diabetes 
An interesting finding of this work relates to the regulation of gene targets through enhancer 
binding. Furthermore, the importance of the complex regulatory networks that assemble at those 
enhancers is gaining more attention. Pasquali and colleagues (Pasquali et al., 2014) found that 
such enhancers posses important SNPs that have been associated with T2D. Exploring whether 
these genetic variations play an important role in the predisposition of beta cells to disease, by 
making them more vulnerable to the loss of identity and function during challenging conditions 
warrants further assessment.  
 
Beta cell heterogeneity 
Deletion of Nkx2.2 in the beta cell population resulted in a variety of cellular responses that were 
translated in the development of different populations within this particular cell type. This 
unexpected outcome pointed to the existence of heterogeneity in the beta cell population, a 
concept that has become more evident and which is receiving an increase amount of attention 
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both in the beta cell and the diabetes field (Ellenbroek et al., 2013; Pipeleers, 1992; Speier et al., 
2007; Wills et al., 2016). I focused on studying and understanding these heterogeneous 
populations, specifically how they differed from each other and the influence they had on the 
phenotypes observed. To do this at the individual cell level, the ideal method was single cell 
RNA-Seq, a procedure that allows you to sort and assess the expression of individual cells (Tang 
et al., 2010). Although this technology has made great progress and has become more widely 
used in other fields, it was not suitable to efficiently undertake this particular challenge at the 
time. Therefore, I opted for different approaches to answer such questions. However, 
optimization of such technology will allow us to more specifically study this heterogeneity that 
seem to play an important role during challenging conditions such as diabetes. Future 
understanding of beta cell heterogeneity could shed light on the existence of markers or 
differences that makes some beta cells more prone to the immune attack present in T1D. It could 
also explore the existence of cells that are more amenable to replication, and understand what 
makes them different from the rest, so that such pathways could be exploited for future 
treatments. Lastly, it could also explain why some cells are more amenable to be differentiate 
during the iPS cell differentiation protocol and others remain in an undifferentiated state 
(Pagliuca et al., 2014; Rezania et al., 2014).  
 
In conclusion, this thesis work has revealed the importance of the function of Nkx2.2 during the 
maturation and adult stage of the beta cell. It has deepened our understanding of the mechanisms 
that regulate beta cell function, and has demonstrated the conservation of Nkx2.2 function in 
both species, then proceeded to show the common features between mice and humans.   
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The findings obtained here have revealed the importance of active repression of non beta cell 
endocrine identities in order to mature and maintain a functional beta cell. Furthermore, they 
demonstrate that such regulation of plasticity is time and context-dependent and requires specific 
signaling mechanisms. This information can be applied in several areas of diabetes therapy that 
may include: the optimization of protocols that aim to differentiate functional beta cells from iPS 
cells, as well as in therapies that aim at re-differentiate beta cells that have lost their identity. 
Both of these approaches are among the most promising therapies that offer the much-needed 
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